Annotation K: Vulvar pain and vulvodynia

Click here for Key Points to Annotation
See more on vulvodynia at  


Since the 1980’s, stunning  advances in research on vulvodynia have fostered better understanding of pain, as well as the intricacies of vulvovaginal anatomy and physiology. The result :a gradual shift away from  the simplistic hope of a singlecause and a single treatment for the pain. Instead, many researchers believe  that pain localized  in the vulvar vestibule requires a holistic perspective: the belief that targeting just the  multifaceted vulvovaginal pain is inadequate.  The pain can be explained only by considering other processes occurring in the body. 

In the early days of patient evaluation, we were armed only with visual inspection, a Q-tip, the patient’s reported pain scale, with very limited knowledge about the vulva, the vestibule, the vagina, and the neurology of pain perception. Today, more health care providers are aware of the global impact of vulvovaginal pain on women’s lives, and researchers are making heroic efforts not only to understand possible causes, but also to evaluate the treatments that have been used up till now and to seek out new treatments that are based on solid evidence. Many topical and oral treatment methods previously thought to be effective for vulvodynia (at least to some extent), are now shown not to have scientific support for efficacy. Currently, studies are being assessed more stringently for validity; randomized controlled trials are encouraged, and consensus on core outcome domains for vulvodynia, that will improve the ability to perform meta analyses, is being sought.12 

It is no small accomplishment that after forty years of confusing research, there is strong evidence that the vulva and vagina have unique inflammatory and immunological properties. Also, specialized immunological blockers (lipids produced endogenously within the body), hold promise as a vestibulodynia treatment by resolving inflammation without impairing the host defense system.3

Studies on brain functioning are clarifying understanding of pain in all spheres of human experience.

The following section, Pain Basics, provides a simple groundwork for better understanding of how pain works in general and also in the vulva and vagina. 





It is no small accomplishment that after thirty years, strong evidence that the vulva and vagina  have the long expected unique inflammatory and immunological properties. Also, specialized immunological blockers  ( lipids produced endogenously within the body), hold promise as a vestibulodynia treatment by resolving inflammation without impairing the host defense system.4

Here, we endeavor to explain as much as possible about vulvovaginal pain.


Multiple professional societies try to contribute clarity to the process of diagnosis by creating terminology and classification systems, but this process can culminate in confusion as well as diagnosis codes. The Diagnostic and Statistical Manual of Mental Disorders (DSM-5), published in 2013, is the primary authority for psychiatric diagnoses.6 is located in this compendium of psychiatric illnesses under the category of sexual dysfunctions and includes the previous terms “dyspareunia” and “vaginismus.” Vulvodynia is ostensibly there as a subset of dyspareunia, though not specifically so. Viera-Baptista, et al and others7 8 warn that there is room for misinterpretation and misunderstanding in this DSM-5 designation, saying, vulvodynia “…is not to be considered a sexual dysfunction, but rather a chronic dysfunctional pain disorder. Dysfunctional pain is defined as a disease state of the nervous system, which arises by its abnormal function, in the absence of neural structural damage.” They also point out that, “vaginismus” and “dyspareunia,” located together, can lead to confusion about the conditions and their therapeutic approaches.9 Bergeron, et al consider that this new categorization actually broadens the scope of definition for vulvodynia, as it allows for vulvar pain, deep pain, and pelvic pain on penetration.10 They mention other pain classification systems that include vulvodynia. The International Association for the Study of Pain (IASP) lists vulvodynia under “chronic primary visceral pain” within subcategories of pelvic pain.11

The 11th revision of the International Statistical Classification of Diseases and Related Health Problems has included vulvodynia within the chronic pain syndromes for the first time.12


The addition of “potential associated factors” to the terminology initiated the deeper study of vulvodynia as a multifactorial process. We have adapted the definitions or rearranged tables below for the purpose of this document, but have stayed true to the intent of the original consensus statement. 


In the 2015 consensus statement, three pain categories were identified, along with “descriptors” related to characteristics of the pain.


1.Vulvar pain related to a recognizable disorder (such as infection, dermatosis, estrogen deficiency, or other identifiable condition) (see Table K1 below), 




  1. Vulvodyniavulvar pain of at least 3 months duration in the absence of clinically identifiable disease, (with possible associated biomedical and psychosocial factors),




  1. Pain with both a specific disorder (e.g. lichen sclerosus) and vulvodynia.


Although originally allocated to the diagnosis of vulvodynia alone, the following descriptors apply to both known conditions causing vulvar pain (especially those causing dyspareunia) AND to vulvodynia. 13 14

  •  Localized (e.g. vestibulodynia, clitorodynia) or generalized or mixed (localized and generalized) 
  • Provoked (e.g. insertional, with contact) or spontaneous (without touch), or mixed (provoked and spontaneous)
  • Primary: with first tampon use or attempt at sexual penetration or secondary: developing after a period of comfortable penetration15 16
  •  Temporally intermittent, persistent, constant, waxing and waning, immediate, delayed, etc.

Associated biomedical and psychosocial factors that may contribute to vulvodynia have been identified (see following list) and form the basis of research into causes.17 These factors may also be seen as determining recognizable subgroups that may benefit from different treatment modalities.18 20 is strongly associated with female sexuality, and is therefore highly impactful for patients and their partners. Women and girls of all ages can be affected but most are in younger age groups, a high proportion under 25 years.21 22 Studies of childhood vulvodynia are few; in many cases, persistent pain is found to have an underlying cause. Despite the pain, the majority of women continue to have sex.23 Dyspareunia in postmenopausal (and 









It is gratifying to lessen pain for one who suffers, and equally disturbing to be unable to help. Pain management of vulvovaginal disorders often entails, for clinicians, a comprehension beyond the level provided in their education or professional experience. Indeed, even clinicians very experienced in diagnosing and treating patients with vulvovaginal complaints are flummoxed by the problem of persistent pain. 

The following section, Pain Basics, provides a groundwork for better understanding of how pain works in general and also in the vulva and vagina. 

Pain is defined as an unpleasant sensory and emotional experience associated with actual or potential damage, or described in terms of such damage.24 It is widely known that a competent system for transmitting pain is essential to the maintenance of the integrity of the body. Pain may be the warning signal that saves the lives of some people or animals, but it destroys the lives of countless others. Chronic pain, clearly, is not a warning to prevent physical injury or disease. It IS the disease—the result of neural mechanisms gone awry.25

The first authors to propose theis differentiation between nociceptive, inflammatory, neuropathic, and dysfunctional pain in vulvar pain were Micheletti et al. [85] in 2014 26




Many types of pain are described, including nociceptive, neuropathic, referred, and complex regional pain syndrome. Since vulvodynia is pain of unknown cause, it is not possible at this time to say what types of pain vulvodynia represents. Vulvar pain caused by a specific disorder may involve any of these types of pain. As our understanding of vulvodynia evolves beyond the rudimentary classification of localized and generalized vulvar pain, nomenclature will be based on a clearer understanding of disease phenotype with improved diagnostic reliability and better defined disease models.27

Nociceptive pain and peripheral sensitization

Acute or nociceptive pain is part of a rapid warning relay instructing the motor neurons of the central nervous system to minimize detected physical harm. It is mediated by nociceptors on A-δ and C fibers. These nociceptors are free nerve endings that terminate just below the skin, in tendons, joints, and in body organs. They serve to detect cutaneous pain, somatic pain, and visceral pain. Nociceptors have been identified in the vulvar vestibule.28  Nociception can be associated with nerve damage caused by trauma, diseases such as diabetes, shingles, irritable bowel syndrome, late-stage cancer, or the toxic effects of chemotherapy. It typically responds well to treatment with opioids and NSAIDs.

Nociceptive pain may be classified according to the type of noxious stimulation:

thermal (e.g. heat or cold),

mechanical (e.g. crushing, tearing, shearing, etc.) and

chemical (e.g. iodine in a cut, chili powder in the eyes).

The “specificity” (whether it responds to thermal, chemical, or mechanical features of its environment) of a nociceptor is determined by which ion channels it expresses at its peripheral end. Dozens of different types of nociceptor ion channels have so far been identified, and their exact functions are still being determined.29

In both somatosensory and viscerally innervated structures, a subgroup of C-nociceptors has been discovered which cannot normally be activated by mechanical or thermal stimuli. These “silent or sleeping” nociceptors become responsive only under pathological conditions such as inflammation. 30

The pain signal travels from the periphery to the spinal cord along an A-delta or C fiber. Because the A-delta fiber is thicker than the C fiber, and is thinly sheathed in an electrically insulating material (myelin), it carries its signal faster (5–30 m/s) than the unmyelinated C fiber (0.5–2 m/s).31 Pain evoked by the (faster) A-delta fibers is described as sharp and is felt first. This is followed by a duller pain, often described as burning, carried by the C fibers.32 These first order neurons enter the spinal cord via a posterolateral tract situated in relation to the tip of the posterior column close to the entrance of the posterior nerve roots (Lissauer’s tract).

A-delta and C fibers synapse on second order neurons in the substantia gelatinosa (laminae II and III of the dorsal horns). These second order fibers then cross the cord via the anterior white commissure and ascend in the spinothalamic tract. Before reaching the brain, the spinothalamic tract splits into the lateral neospinothalamic tract and the medial paleospinothalamic tract.33

Second order neospinothalamic tract neurons carry information from A-delta fibers and terminate at the ventral posterolateral nucleus of the thalamus, where they synapse on third order neurons (dendrites of the somatosensory cortex), and the message is interpreted as pain. Pain-related activity in the thalamus spreads to the insular cortex (thought to embody, among other things, the feeling that distinguishes pain from other homeostatic emotions such as itch and nausea) and anterior cingulate cortex (thought to embody, among other things, the motivational element of pain).34 These fibers are responsible for the protective (adaptive) reflex of jerking the hand away after burning a digit on a hot stove.

If the hand stays on the stove and there is injury to a peripheral nerve, spontaneous ectopic activity in abnormally regenerating neurons stimulates abnormal excitability and hypersensitivity to mechanical stimuli, as well as chemical and thermal stimuli.35 The threshold for its activation falls, and responses to subsequent inputs are amplified. There is increased firing of the nociceptive fibers and increased sensitivity of the A fibers. This is peripheral sensitization, leading to the thought that is most perplexing to clinicians: How can simple touch hurt? Allodynia arises from hypersensitivity to stimuli that are not normally painful.  In the case of the vulva with peripheral sensitization, allodynia means that touching in the vestibule hurts. In a similar fashion hyperalgesia, increased response to stimuli which are normally painful, creates heightened pain. Heightened pain sensitivity (both allodynia and hyperalgesia) immediately after injury is still a beneficial effect, but pain that persists beyond healing is an aberration of normal functionality.

In the absence of ongoing tissue injury, this state of heightened sensitivity returns, over time, to the normal baseline where high-intensity stimuli are again required to initiate nociceptive pain.

Nociceptive pain and central sensitization

If the sensitization persists over time, then central sensitization will occur. Intense or prolonged painful stimuli cause an exaggerated release of glutamate from peripheral nociceptive afferents located with dorsal horn neurons in the spinal cord. Bombarded by glutamate and release of excitatory and inflammatory neuropeptides, N-methyl-D-aspartate (NMDA) receptors in dorsal horn neurons are up-regulated and increase the number of synapses present on the neurons. This leads to neuronal excitability to noxious and innocuous stimuli. It also produces pain hypersensitivity in non-inflamed tissue by changing the sensory response elicited by normal inputs and increases pain sensitivity long after the initiating cause may have disappeared and when no peripheral pathology may be present. Because central sensitization results from changes in the properties of neurons in the CNS, the pain is no longer coupled, as acute nociceptive pain is, to the presence, intensity, or duration of particular peripheral stimuli. Instead, central sensitization represents an abnormal state of responsiveness or increased gain of the nociceptive system. The pain is effectively generated as a consequence of changes within the CNS that then alter how it responds to sensory inputs, rather than reflecting the presence of peripheral noxious stimuli. This represents a major functional shift in the somatosensory system from high-threshold nociception to low-threshold pain hypersensitivity. For example, a woman has experienced pain as arising from “down there,” and in consequence imagines that it is actually triggered by noxious stimuli where she feels the pain. Central sensitization reveals, however, that this in many cases is a sensory illusion; specific alterations in the CNS can result in painful sensations occurring in the absence of either peripheral pathology or noxious stimuli. Target for treatment in central sensitization must the the CNS and not the periphery. 36

This ability of the nervous system to make adaptive changes to injury or pathophysiologic change, called neuroplasticity, is an essential function.

Figures 1 A-C show a schematic diagram of a physiological model for nerve sensitization. 37


Figure 1-A shows the immediate response of nociceptive fibers to cutaneous trauma. Action potentials propagate through the dorsal root ganglion to the spinal cord to activate and sensitize wide dynamic range (WDR) neurons with axons ascending to higher centers.

Figure 1-B shows the now sensitized WDR responding to activity from touch of the large diameter A-mechanoreceptors activated by light touch.

Figure 1-C shows that with activity from central sensitization, the neurons can discharge spontaneously when there is no noxious stimulus in the periphery.

The combination of peripheral sensitization and central sensitization causes neuropathic pain, a maladaptive response of the neural network to injury, disease, trauma, and inflammation that results in chronic pain. Central sensitivity may be a common etiology for a group of medically indistinct (or nonspecific) disorders, such as fibromyalgia, chronic fatigue syndrome, and irritable bowel syndrome.38

Neuropathic pain

Neuropathic pain is caused by damage to the neurons in the peripheral and central nervous systems and involves sensitization of these systems. 39

As with nociception, ongoing tissue damage, increased density of several transducers, and activation of receptors results in increased channel activity and sensitivity to noxious stimuli (peripheral sensitization). Oscillations of membrane potential, abnormal firing, and generation of ectopic activity in afferent nerves result. Neurons can exhibit cross-talk (ephaptic transmission) between peripheral fibers and their cell bodies within the dorsal root ganglion, increasing pain signals to the brain (central sensitization). 40 There is an increased response to stimuli which are normally painful (hyperalgesia) and abnormal sensory signs such as allodynia (pain as a result of a stimulus which does not normally provoke pain). Along with the nociceptive changes, sympathetic efferents become able to activate nociceptive fibers via α-adrenoceptors to achieve sympathetically maintained pain.41

Sources of neuropathic pain include trauma, spinal cord injury or compression, ischemic injury, diabetic neuropathy, infection/inflammation, cancer invasion/compression of neural structures, and drugs such as vinca alkaloids.

Peripheral neuropathic pain is often described as “burning”, “tingling”, “electrical”, “stabbing”, or “pins and needles.”42

The majority of research into neuropathic pain mechanisms has concentrated on changes in a peripheral nerve or spinal cord after peripheral nerve injury. It is important to recognize that alterations in the brain have also been demonstrated following peripheral nerve injury, but much less is known about these changes.43

Another challenge for researchers and clinicians alike is that chronic pain may involve a mix of both inflammatory and neuropathic components. Inflammatory nociceptive pain may damage neurons and produce neuropathic pain. Likewise, neuronal injury may cause an inflammatory reaction that contributes to inflammatory pain.

In the scientific community, two major views on pain processing exist. One states that pain results from specific pathways made up of distinct sets of neurons peripherally as well as centrally. The other claims that pain is not signaled by a specific system of neurons, but instead by activation in multimodal neurons that also react to other sensory stimuli.44 This second viewpoint embodies the concept of pain as a multi-factorial condition.

Experts believe that the idea that pain belongs only to a somatosensory system needs revision. And recent advances in cellular and molecular science suggest a conceptual shift: if gene expression and regulation, intracellular mechanisms, and anatomical and physiological characteristics are taken into account in characterizing a pain transmission system, then this system is homologous with the different interoceptive systems (relating to stimuli that are internal to an organism’s homeostatic systems) compared with the classic exteroceptive systems (relating to stimuli that are external to an organism’s somatosensory systems).45 The interoceptive homeostatic systems such as those that monitor body status through temperature regulation, visceral sensations, hunger, thirst, respiration, and itch, strive to maintain an optimally balanced state for the organism. Pain processing as part of this homeostatic network implies a close connection between the nociceptive system or neuropathic system and the autonomic nervous system, the hypothalamic–pituitary–adrenal-axis, and other neuroendocrine systems.

This view may also explain the different aspects of pain dealt with in the clinical setting and opens up the possible need to consider that certain pain conditions depend on homeostatic dysfunction rather than on actual tissue damage.46

Gender related variation in pain response

Sex differences in pain have been consistently reported in both clinical and experimental literature. In general, women are more likely to develop chronic pain syndromes and are more sensitive to experimental pain than men.47 As a population, women show greater pain sensitivity, less tolerance to pain, and more somatization than do men.48 In reference to chronic pain conditions, there is a two to six-fold greater prevalence of chronic pain conditions in women as compared to men.49 50 The basis for these differences between men and women, however, is poorly understood.51 How estrogen may be related to pain in general and the increased tendency to pain in women has been questioned for years.

Influences of sex hormones on pain

Estrogens have an extraordinarily wide range of actions in the human body. Not only do they exert profound effects on sexual differentiation and behavior, but they also modulate cardiovascular function, bone formation, hemostasis, water and salt balance, and metabolic rate. Abundant evidence demonstrates that sex hormones, such as estrogen, influence somatic sensory processing with the brain as one of the major targets. The production of estrogen in the brain, as well as the complexity and detail of estrogen function in the central nervous system, is now evidenced in an increasing number of studies.

Hormone-influenced variations in sensation include size of sensory fields throughout the body, level of sensory response, and pain thresholds. Variations in hormone levels are also a factor. We know, for example, that the genital sensory field of the female rat is expanded by estrogen treatment, and that estrogen increases the sensitivity to stimulation in the sensory field, which is innervated by the pudendal nerve.52 In postmenopausal women, improved sensation to mechanical stimuli can result from a topical estradiol cream on the vulvar vestibule.53 When levels of sex hormones are elevated, as in pregnancy, pain threshold is likewise higher.54

But, less pronounced levels of sex hormones, occurring with the estrous or menstrual cycle will still affect pain sensitivity.55 Interest in these findings is increased by the possibility that hormonal factors may play a pivotal role in pain conditions (such as fibromyalgia) which affect women disproportionately.56

Estrogen regulation of vaginal sensory and autonomic nerve density

Estrogen receptors are abundant in vaginal tissue,57 influencing vaginal function through direct effects on vaginal target cells with vaginal epithelial cell proliferation and vascular remodeling.58 It is well established that declining estrogen levels in the postmenopausal period can contribute to vaginal dysfunction by depriving target cells of trophic support.

Historically, the vagina has been inaccurately considered as sparsely innervated. From animal studies, the mammalian vagina is actually richly imbued with sensory, parasympathetic, and sympathetic nerve fibers. Sensory nociceptor and tactile nerves are present within the dermis and connective tissue, and autonomic sympathetic and parasympathetic fibers abundantly innervate vaginal smooth muscle and vasculature.59 In the last two decades, immunohistochemical markers have allowed progress in identification of human vaginal innervation, a mixture of both sensory and autonomic nerve fibers.  The nerve supply of the introitus, hymen, and vagina comes from the autonomic nervous system’s vaginal plexus. The sensory nerve fibers come from the pudendal nerve. The anterior vaginal wall has more nerve fibers than the posterior. There are few free nerve endings in the upper two thirds of the vagina. In some areas, an extreme number of richly innervated and non-innervated blood vessels immediately beneath the epithelium are noted.60 These nerves are believed to play important roles in mediating vaginal sensitivity and pain, and in regulating blood flow, secretions, and tonus of the vaginal wall.61

Sustained 17b-estradiol administration reduces innervation density to an extent comparable to that of estrus, implying that estrogen is the hormone mediating vaginal neuroplasticity. These findings indicate that some aspects of vaginal dysfunction during menopause may be attributable to changes in innervation. Increased sympathetic innervation may augment vasoconstriction and promote vaginal “dryness,” while sensory nociceptor axon proliferation may contribute to symptoms of pain, burning, and itching associated with menopause and some forms of vulvodynia.62

Spinal ER-neurons and their relation to nociceptive transmission at the spinal level

The brain is one of the major targets of estrogen action. In the central nervous system, estrogen has an extensive impact on many of the cardinal brain systems. In particular, the presence of estradiol concentrating cells and estrogen receptors (ERs) in the forebrain and upper brainstem have been known for a long time, since these are the areas governing reproductive effects of estrogen.

Estrogen and the endogenous opioid system

The mechanisms through which estrogen and other sex hormones affect sensory processing and pain sensitivity have long remained obscure. However, recent work on the distribution of estrogen receptors in the central nervous system has provided some insight.63

Estradiol may bind to estrogen receptors on cell membranes, affecting intracellular pathways and modulating ion channels, trans-membrane receptors, and transcription. In addition, many of estradiol’s effects are ascribed to binding to intracellular estrogen receptors (α and β), which, when they bind to estrogen, in turn, bind to specific gene sequences known as estrogen response elements (ERE), thereby inducing transcriptional activity of that gene.64

Estrogen receptors are densely expressed by cells located in the superficial layers of the spinal dorsal horn. This is the critical area of the central nervous system where the initial processing of pain sensation occurs.65 These estrogen sensitive cells in the dorsal horn exert their effect by influencing opiate synthesis, (release of encephalin) similar to the production of opiates by hypothalamic estrogen receptor expressing neurons. Thus, they are crucial components of the endogenous pain-inhibitory system. They are the local circuit neurons that mediate both presynaptic and postsynaptic inhibition onto nociceptive relay cells. They are activated by primary nociceptive and non-nociceptive afferent fibers as well as by descending fibers from pain-modulatory centers in the brainstem.

Yet another mechanism may explain estrogen dependent changes in men and the finding that estrogen- related changes in pain sensitivity are not generalized but are regionalized and tissue-specific.66 Cells in the superficial dorsal horn express aromatase,67 the enzyme that catalyses the transformation of androgens into estrogens and governs the synthesis of estrogen from cholesterol. Decades ago, the presence of aromatase was shown in the brain,68 where it plays a crucial role in the regulation of sexual differentiation of the brain and the activation of male sexual behavior. Production of aromatase in the superficial horn cells implies that the resulting locally produced estrogen may influence sensory processing at the level of the spinal dorsal horn. The estradiol may then act locally in an autocrine (stimulating receptors on the same cell) or paracrine manner (stimulating an adjacent cell of a different type). Signaling in primary afferent or descending fibers that terminate in the superficial dorsal horn may modulate aromatase activity. 69

Why might estrogens affect the nociceptive system?

It is possible that the diverse effects of estrogens relate to their phylogeny as one of the most ancient hormones, evolving about 500 million years ago.70 Work with vertebrate steroid receptors suggests that the estrogen receptor (ER) was the first steroid receptor, and that it is possible that estrogen regulation may be the most ancient model of steroid regulation.71. It is hypothesized that the ER evolved before its estrogen ligands. Thus, estrogen worked as an independent transcription factor; this independent function explains why estrogen, rather than any other steroid, exerts such a wide variety of effects in so many different tissues and species. It is further suggested that, since ER is one of many widespread transcription factors used in sensory processing, it came to modulate nociceptive transmission as well.

Estrogen and cyclical pain sensitivity

Many studies of healthy women show higher pain sensitivity during periods of low estrogen levels, 72 but the basis for these differences is incompletely understood. A recent study assessed how pain-related neural processing, as measured by brain activity, varies across the menstrual cycle in 15 normally cycling, healthy women, and whether menstrual cycle effects are based on fluctuating sex hormone levels. Cycle-related changes in pain sensitivity measures and brain activation were only partly explained by varying sex hormone levels. Pain-related cerebral activation varied significantly across the menstrual cycle, even when perceived pain intensity and unpleasantness remained constant. The involved brain regions suggested that cognitive pain or more general bodily awareness systems are most susceptible to menstrual cycle effects.73

Other studies report that hormone levels were not found to be consistent predictors of pain severity in post-menopausal women.74 Meta-analyses of variations in pain perception across the menstrual cycle suggest that the differences, if they exist at all, are small. 75

In addition, the large variation in standardizing cycle phases and frequent omission of blood serum analyses to verify menstrual cycle stage have resulted in inconsistent findings as to the time in the menstrual cycle that pain is most significant.76

It appears that while hormonal influences exist, the effects of estradiol may not be easily explained or narrowed to one specific mechanism designated as either “anti-nociceptive” or pro-nociceptive.”77

Postmenopausal dyspareunia, traditionally considered the result of hypoestrogen and vulvovaginal atrophy, is also not adequately explained by a hormonal model. Pain is also influenced by cognitive, affective, and dyadic factors. And, in comparison with hormone levels in one study, cognitive-emotional variables (e.g., catastrophization, depression, anxiety) were found to be stronger predictors of pain than hormonal levels. In addition, the maturation value was a significant predictor of both induced and intercourse-related vestibular pain.

Although estrone was inversely correlated with labial and vaginal pain, both estrone and estradiol do not account for a significant amount or variance in pain intensity in any location. Progesterone is associated with induced vestibular pain and is the only hormone that provides a unique statistical contribution toward pain intensity in multiple regression studies. Findings from animal research suggest that progesterone may have a dose-dependent inhibitory effect on the analgesic properties of estradiol at lower levels.78

It would also appear that, while estrogen levels may not be directly related to pain intensity, a minimum threshold for percentage of depletion is needed at certain peri-or postmenopausal periods to induce physiological changes that trigger pain sensitivity.

Oral contraceptives and pain

A number of studies have questioned the role of oral contraceptives (OC) and vulvovaginal pain.

An association between what was formerly vulvar vestibulitis syndrome (VVS) and OC was reported in 138 women whose symptoms had appeared during the previous two years. Their responses, compared with those of 309 age-matched controls, showed that only 4% of women with VVS had never used OCs compared with 17% of controls.79

Development of pain in OC users is attributed to a hypoestrogenic state with vulvovaginal atrophy. In addition, decrease in estrogen receptor levels has been noted in tissue taken from women with VVS compared with controls.80

Significant differences in pain thresholds for stimulation with von Frey filaments were observed in women using oral contraceptives. The most sensitive area was the posterior vestibule.81

Of women treated in an Israeli clinic for vulvar vestibulitis syndrome (VVS), 51% used OC with 20 mcg or less estrogen, and 65% used pills with 30-35mcg estradiol.82

In a recent cohort study, women who developed vestibulodynia while taking OC were more likely to have longer cytosine-adenine-guanine (CAG) repeats in the androgen receptor (AR) than the women who took the same type of OC but did not develop vestibulodynia. The researchers speculated that the risk of developing vestibulodynia related to OC may result from lowered free testosterone combined with an inefficient AR that predisposes women to vestibular pain.83

In contrast to the positive associations of pain with OC use, other investigators suggest that there is no relationship. Danielsson et al found no association between OC use and VVS in over 3,000 women questioned about painful intercourse and OC use.84

In analysis of population-based cases and controls, oral contraceptive use was associated with a non-significant 30% increase in the risk of vulvodynia (95% Ci 0.7-2.3). The findings did not support the strong associations observed in clinic-based studies; the fact that more low-estrogen OCs were used in some study groups does not allow for a cause-and-effect conclusion. Harlow et al noted that, in their study, clinically confirmed clinic based cases, as compared to population-based cases, were more often OC users, earlier-age users, and users for longer periods. Thus, observational studies using clinic-based cases might not adequately represent OC use in all women with vulvodynia.85

In women taking 20 mcg ethinyl estradiol combined OCs and women not on OC, free testosterone levels were lower in OC users. There were no differences in Female Sexual Functioning Index (FSFI), clitoral thermal or vibratory thresholds, or vestibular pain thresholds between groups.86

To determine whether previous OC use increases risk for vulvodynia, a population based cohort of women in SE Michigan found that women < 50 years of age with current or past vulvodynia were no more likely to have taken OCs than were women without a history of vulvar pain.87

As definitive evidence is awaited, many women will stop OC on their own to see if cessation makes any difference, and many clinicians will encourage a trial off OC for the same reason.

Referred pain

The convergence in the dorsal horn of the spinal cord of afferent impulses from viscera, skin, and muscle can lead to the phenomenon of referred pain. Pain is commonly referred to the vulva from sacro-iliac joints and pelvic floor muscles as well as the bladder.88 On the other hand, this convergence can influence sensation in nearby viscera. Bladder pain can develop when vulvar pain is present; a common presentation of vulvar pain includes urinary tract symptoms of frequency, urgency, and dysuria.89

Co-morbidities and complex regional pain syndrome

Co-morbidities and other pain syndromes such as painful bladder syndrome, fibromyalgia, irritable bowel syndrome, and temporomandibular disorder, have long been reported by women with vulvovaginal pain.90 91 92  A recent study assesses the characteristics of 236 women with provoked vulvodynia alone and 55 women with provoked vulvodynia and co-morbid chronic pain. Compared with some with provoked vulvodynia alone, women with provoked vulvodynia and concurrent pain reported a significantly longer duration of pain, pain radiating to other parts of the vulva , and pain interfering in a variety of daily activities.93

Patients with severe co-morbid pain can develop complex regional pain syndrome (CRPS), formerly called reflex sympathetic dystrophy. CRPS, a combination of sensory, autonomic, and motor dysfunction, may develop spontaneously or after an identified nerve injury. CRPS is believed to be the mechanism connecting, for instance, pelvic pain related to endometriosis, painful bladder symptoms, provoked and/or spontaneous vulvar pain, and pelvic floor muscle dysfunction. Clinicians caring for women with provoked vulvodynia and concurrent chronic pain must be alert to the potentially greater health needs in this sub-sample of women.94



In 1976, vulvar pain was officially recognized by the International Society for the Study of Vulvovaginal Disease (ISSVD) with the term “burning vulva syndrome.”

The 2003 ISSVD Terminology and Classification of Vulvodynia divided vulvar pain into two major groups:

  1. vulvar pain related to a known disorder
  2. vulvar pain in the absence of relevant visible finding or clinically identifiable disease.95 This second group is termed vulvodynia

Vulvodynia was divided by location to generalized or localized, depending on the distribution of the pain, and in 2012, further sub-typed into provoked, unprovoked, or mixed pain.

Further understanding of vulvar pain and vulvodynia comes with the recent update on pain definitions from the ISSVD, presented in its entirety.

2015 ISSVD Consensus Terminology and Classification of Persistent Vulvar Pain

Table 1: 2015 Consensus Terminology and Classification of Persistent Vulvar Pain

A. Vulvar pain caused by a specific disorder*

  • Infectious (e.g. recurrent candidiasis, herpes)
  • Inflammatory (e.g. lichen sclerosus, lichen planus, immunobullous disorders)
  • Neoplastic (e.g. Paget disease, squamous cell carcinoma)
  • Neurologic (e.g. post-herpetic neuralgia, nerve compression or injury, neuroma)
  • Trauma (e.g. female genital cutting, obstetrical)
  • Iatrogenic (e.g. post-operative, chemotherapy, radiation)
  • Hormonal deficiencies (e.g. genito-urinary syndrome of menopause [vulvo-vaginal atrophy], lactational amenorrhea

B. Vulvodynia – Vulvar pain of at least 3 months duration, without clear identifiable cause, which may have potential associated factors


  • Localized (e.g. vestibulodynia, clitorodynia) or Generalized or Mixed (Localized and Generalized)
  • Provoked (e.g. insertional, contact) or Spontaneous or Mixed (Provoked andSpontaneous)
  • Onset (primary or secondary)
  • Temporal pattern (intermittent, persistent, constant, immediate, delayed)

*Women may have both a specific disorder (e.g. lichen sclerosus) and vulvodynia

Table 2: 2015 Consensus Terminology and Classification of Persistent Vulvar Pain – Appendix: Potential Factors Associated with Vulvodynia*

  • Co-morbidities and other pain syndromes (e.g. painful bladder syndrome, fibromyalgia, irritable bowel syndrome, temporomandibular disorder) [Level of evidence 2a]
  • Genetics [Level of evidence 2b]
  • Hormonal factors (e.g. pharmacologically induced) [Level of evidence 2b]
  • Inflammation [Level of evidence 2b]
  • Musculoskeletal (e.g. pelvic muscle overactivity, myofascial, biomechanical) [Level ofevidence 2b]
  • Neurologic mechanisms:
  • Central (spine, brain) [Level of evidence 2b]
  • Peripheral [Level of evidence 2b]
  • Neuroproliferation [Level of evidence 2b]
  • Psychosocial factors (e.g. mood, interpersonal, coping, role, sexual function) [Level of evidence 2b]
  • Structural defects (e.g. perineal descent) [Level of evidence 2b]

*The factors are ranked by alphabetical order


Further interpretation of  the 2015 pain classification

Since 1976, clinicians have designated any persistent vulvar pain that they were unable to diagnose as “vulvodynia.”

Now, in 2019,  it is recognized that there are a number of accepted causes of vulvar pain, as well as a number of other probable causes of vulvar pain needing further evidence to become accepted.  Thus, the new title Consensus Terminology and Classification of Persistent Vulvar Pain moves away from pain of unknown cause (vulvodynia) and gives clinicians  a number of possible sources to explore in a workup before giving the diagnosis of vulvodynia. As our understanding of vulvodynia evolves beyond the rudimentary classifications of localized provoked vulvodynia and generalized vulvodynia, nomenclature will be based on a clearer understanding of disease phenotype with improved diagnostic reliability and better-defined disease models.96

Terms no longer in use include: essential vulvodynia, dysesthetic vulvodynia, burning vulva syndrome, vestibular adenitis, vestibulitis, vulvar vestibulitis syndrome, and vestibulodynia (although this last term may persist). Clinicians need to be aware of these labels because they appear in studies done prior to 2015.

Localized provoked vulvodynia (LPV) is most common, especially in premenopausal women97, 98 while generalized vulvodynia is more common in peri-and postmenopausal women99.

Etiology of pain caused by a specific disorder

Vulvar pain from a specific disorder is caused by the pathology of that disease. Table K-1 Possible causes of vulvovaginal pain from specific disorders and associated annotation links lists the known causes of vulvar and vaginal pain. These recognizable disorders can be identified by the process laid out in our algorithm: careful history that includes review of symptoms (Annotation A), attention to possible systemic or autoimmune diseases or history of atopy, sexual history, psychological profile (Annotation B), lifestyle issues (Annotation J),  targeted non-genital and genital exams (Annotation C) (Annotation D), including assessment of vulvar architecture (Annotation F) and skin (Annotation H), pain and symptom mapping (Annotation I), evaluation of tolerance for the exam (Annotation D), the vagina (Annotation N) (Annotation O) and the pelvic floor (Annotation L), and evaluation of vaginal pH and secretions through wet prep and other tests (Annotation P).

By taking these steps, which may include testing such as STI testing and yeast culture (Annotation P) or vulvar or vaginal biopsy (Annotation G), disorders that the clinician may not even be aware of will be discovered and can then be treated. It is hoped that treating the condition will also treat the pain. This is not always the case. Because of the pain mechanisms described in Pain Basics, pain sometimes persists despite treatment: a specific disorder and vulvodynia can co-exist.

Table K-1 Possible causes of vulvovaginal pain from specific disorders and associated annotation links

Candida vaginitis (P) Cellulitis (Atlas of Vulvar Disorders)
Desquamative inflammatory vaginitis (DIV) (P) Systemic diseases, e.g., Crohn (Atlas of Vulvar Disorders) Sjögren (O)
STIs: trichomonas (P), herpes (M), chancroid (M) Fistulas (O)
Hypoestrogenization (genitourinary syndrome of menopause or lactational atrophy), inadequate lubrication (O) (Atlas of Vulvar Disorders) Drug reaction (O)
Irritants and allergens, irritant or contact dermatitis (J)(H) (Atlas of Vulvar Disorders) Congenital anomalies (imperforate hymen (Q), vaginal septum) (N)
Dermatoses with erosions, fissures (e.g. lichen sclerosus, lichen planus) (H) (Atlas of Vulvar Disorders) Squamous cell carcinoma, other cancer and treatment for cancer, (Atlas of Vulvar Disorders), Extramammary Paget Disease (Atlas of Vulvar Disorders)
Dermatoses with ulcers (e.g. aphthous ulcers, pemphigus, pemphigoid) (H) (Atlas of Vulvar Disorders) Seminal plasma allergy (Atlas of Vulvar Disorders)
Plasma cell vulvitis (Atlas of Vulvar Disorders) Pudendal nerve compression or neuroma (K)
Trauma (obstetrical, female genital cutting) (Atlas of Vulvar Disorders) Iatrogenic (post-op, post radiation or chemotherapy) (Atlas of Vulvar Disorders)
Psychosexual issues leading to poor sexual arousal, vaginismus (D)

Etiology of pain from vulvodynia

Vulvodynia is, by definition, idiopathic, without known etiology. On exam, the genitalia usually look normal. There may be some erythema, especially with gentle touch with a Q-tip. The patient feels pain with touch out of proportion to any abnormality that can be seen with the naked eye or with a magnifying glass. It is, therefore, a diagnosis of exclusion; a clinician must be able to say that the pain is not caused by a specific disorder (Table K-1). However, it is prudent to look for increasingly recognized potential factors associated with vulvodynia.  (See Table K-2)

Table K-2 Potential factors associated with vulvodynia and associated annotation links

Co-morbid and other pain syndromes- Regional Pain Syndrome (K) Interstitial cystitis, painful bladder (L)
Structural defects (perineal descent) (L) Pelvic floor dysfunction (L)
Hypoestrogenization, inadequate lubrication (O) (Atlas of Vulvar Disorders) Musculoskeletal conditions (L)
Pudendal neuralgia (K) Psychosexual issues leading to poor sexual arousal, vaginismus (D)
Hormonal factors, pharmacologically produced (oral contraceptives) (K) Genetic

A pain syndrome that may be a form of vulvodynia or may be vulvar pain from a (known) specific cause is pudendal neuralgia (PN). Pudendal neuralgia is defined as a syndrome of neuropathic pain in the distribution of the pudendal nerve. It was at one time definitely considered a cause or type of vulvodynia,100 but the increase in knowledge over the past two decades has more clearly defined PN as pain from a known specific cause of vulvar pain-the pelvic floor muscles. More evidence is needed; there is no evidence to support the automatic diagnosis of pudendal entrapment when the pain in the area supplied by the pudendal nerve is present.

The cause of the PN is not always clear, but it is believed to result from nerve injury caused by stretching or compression. 101 Such injuries include fracture of the pelvis (ischial spine), entrapment of the nerve on its route adjacent to the ischial spine, between the sacrotuberous and sacrospinous ligaments,102 or by compression of the nerve as it courses through Alcock’s canal. The nerve may sustain injury from cycling,103 infectious damage by herpes simplex,104 tumors, or chemoradiation. The nerve may be damaged by stretching from chronic constipation, perineal descent, or fetal descent in second stage labor. Iatrogenic injury may result from pudendal nerve blocks, following transobturator inside-out tape procedure,105 following transvaginal mesh surgery, 106 sacrospinous ligament fixation, or as damage to the nerve or its blood supply during any type of surgical intervention requiring exploration of the pelvis. Traction on the lower extremities for orthopedic surgical procedures on the fracture table has also been suggested to be a cause of PN.107 Acknowledging the transitional status of pudendal neuralgia, we have put the condition in both Table K1 and K2.

Likewise, we have placed psychosexual issues leading to poor sexual arousal and vaginismus on both lists. We have worked with women who have been able to understand that overactive pelvic floor muscles are causing involuntary tightening of the vagina, who have had resolution of what was thought to be vulvodynia. It is important for clinicians to understand, however, that, if they see nothing “abnormal” on exam, vaginismus is not a “given” diagnosis.

As more is learned about the causative factors associated with vulvodynia, those factors, with the proper evidence, will move up to the category of vulvar pain from a specific disorder.


Vulvodynia as an inflammatory condition has been extensively debated. The vulvar vestibule is derived from endoderm and therefore has immunology similar to the mucosa of the gastro-intestinal tract. Study of  vulvar immunology provided some insight into LPV. In localized provoked vulvodynia (LPV) different vulvovaginal infections, such as recurrent candidiasis as well as urinary tract infections, have been considered as risk factors for disease.108 109 110 A localized hypersensitivity to Candida (yeast) has been described in LPV.111

Histopathology from the vulvar vestibule has often shown increased lymphocytic infiltrates in the vestibular mucosa.112  113 But the characteristics of the inflammatory response have never been well elucidated. Since several studies have found no evidence of classic active inflammation, there has been a tendency to abandon inflammation as a source of pain in the vulvar vestibule.114 115

Instead, attention has focused on exaggerated inflammatory response; dysregulation of inflammation in affected women has been suggested.116 117 118 119

The vestibular mucosa of LPV patients characteristically has an increased number of exceptionally superficial nerve endings.120  One study suggested that an increased number of mast cells producing heparanase enzyme boosts nerve growth.121 However, the role of mast cells has not been fully proven.122 A recent study has shown no increase in mast cell density in patients with confirmed vulvodynia versus racially matched controls.123

 As the immune and neuronal systems are often closely interrelated, an increased inflammatory response may well predispose to the development of a pain syndrome such as LPV.124

Researchers recently focused on the characteristics of the local immune system by immunohistochemical analysis of different immune cell types in the vestibular mucosal tissue. In  27 LPV patients and 15 controls, they demonstrated the presence of key immune players and found evidence of immune activation in LPV.125

Mucosal surfaces of the human body are known to contain secondary lymphoid tissue, the mucosa-associated lymphoid tissue (MALT).126  In MALT, B and T lymphocytes organize to form germinal centers, which play a central role in initiating an immune response against foreign antigens such as those from viruses and bacteria. The crucial point in the initiation of an immune response is the presentation of foreign antigens to T lymphocytes. Macrophages, dendritic cells (DCs), and B cells are called professional antigen-presenting cells. With antigen presentation, the T cells become activated. The activated T cells, in turn, are capable of activating a whole range of immune cells to mount different types of responses depending on the nature of the initial insult. This part of the activation of an adaptive immune response takes place in germinal centers. A proportion of the activated cells are B cells developing into antibody-producing mature plasma cells. In mucosal areas, B cells switch into plasma cells producing dimeric IgA-class antibodies that will subsequently be transported across the epithelium to the mucosal surfaces.

More B lymphocytes and mature mucosal IgA-plasma cells were found in patients than in controls (  P  < .001 and  P  < .001, respectively). In LPV samples, B and T cells were arranged into germinal centers representing local immune activation. Germinal centers were not seen in controls. Antigen-presenting CD163  (DCs) and CD68 macrophages were found both in patients and controls with similar densities. DCs were found to extend their dendrites into the luminal space through an intact epithelium. Similar amounts of mast cells were found evenly scattered throughout the stroma of vestibular mucosa of both patients and controls.

Thus, the vestibular mucosa seems to have its own organized immune system that could be called VALT, similar to other endoderm derived mucosal surfaces of the human body containing secondary lymphoid tissue, called MALT.127 Furthermore, the findings of germinal centers and large numbers of B cells and plasma cells support immune activation in LPV. In contrast, other types of immune cells, like macrophages and mast cells, were present in equal densities both in the patient tissues and healthy mucosal tissues.128

More concrete evidence in support of the unique, embryologically defined, inflammatory/immunologic responsiveness in the vulvar vestibule was demonstrated in a study of fibroblast strains derived from two regions of the lower genital tract in LPV cases and pain-free controls. The fibroblasts were challenged with six separate stimuli: live yeast species of Candida albicans, C. glabrata, C. tropicalis, S. cerevisiae, yeast extract (zymosan), or an inactive vehicle. Production of prostaglandin E2 (PGE2) and interleukin-6 (IL-6) were measured as pro-inflammatory markers. Highest IL-6 and PGE2 occurred with vestibular fibroblast strains following C. Albicans, C. glabrata, and zymosan challenges. Researcher believe that this enhanced site-specific innate immune responsiveness to yeast pathogens by fibroblasts may be an early step in LPV pathogenesis. 129

Further support of the fundamental role of inflammation and immune activation in LPV comes from a study of vestibular mucosal specimens from 17 patients with LPV and from 15 controls. Excessive epithelial nerve growth in LPV was associated with increased B cell inflammation.130

Disorder of the central nervous system/other pain syndromes

There is increasing recognition that vulvodynia may be a disorder of the central nervous system because:131 (1) It is chronic pain and this, by definition, involves changes in the central nervous system, perpetuating the pain through central sensitization.132 (2) Women with vulvodynia have an increased incidence of other chronic pain syndromes,133 (3) Vulvodynia patients have evidence of systemic sensory dysregulation with increased perception of noxious stimuli not only at the vulva but also at sites distant to the genitalia.134,135 In addition, chronic pain is a disease process itself and does not need to be validated by a visible cause, such as a lesion. Although there may be a triggering source of pathology, the mechanisms that perpetuate the pain result primarily from central nervous system changes (or plasticity) as central sensitization occurs.

Pain and the brain: stress

The pain of vulvodynia probably results from more than one cause, or a combination of factors–all of which differ from woman to woman–and all best understood within the framework of what neuroscience has discovered: that there is a entire system of mind-brain-body interactions related to genetic and psychosocial risk factors, biological and/or infectious triggers, coping skills, and personality traits that affect how the brain perceives, processes and manages pain. None of these studies supports causality, but at times, the absence of identifiable physiologic pathology has led to the view that the pain may be solely due to psychological factors. This position may be as erroneous as emphasizing only the physiological aspects of the conditions.136

In response to stressors of the external and internal environment, the body produces hormonal and neurotransmitter mediators that turn on cellular and tissue responses throughout the body, and lead to coordination of physiological response to the circumstances at hand.137 Research has reinforced the fact that classic “fight or flight” stress mediators have protective as well as damaging effects. As researchers endeavor to discern which mediators protect and which damage, a new formulation addresses the relationship between challenges from the environment and biological response.

In place of the ambiguous term stress, two new concepts have been formulated. Allostasis represents the brain’s constant effort to process daily physical, environmental, social and psychological stressors and return the body to a steady state of balance or homeostasis. With allostasis, there is stability, or homeostasis, during change. Allostatic load refers to the wear and tear that the body experiences from repeated cycles of allostasis, as well as the inefficient ignition or shut down of these responses. 138 When the body is unable to return to homeostasis, allostatic load increases and is manifested as loss of resilience and increased risk of disease. Fear, including social fear, is a significant trigger of the stress response139 and a source of allostatic load. 140

Repeated exposure to stress either through early or chronic exposure causes wear and tear on the body’s ability to sustain balance and resilience. It is possible that stressful or traumatic life events in the past may “prime” the brain to contribute to the onset of pain. Adverse life events such as destructive relationships, parental divorce or adverse childbirth experiences are more frequent in women with vulvodynia than in women without.141

In a population based study, women with vulvodynia were 2.6 times more likely to report lack of family support (comfort, encouragement and love). Women who developed vulvodynia as adults were significantly more likely to report childhood abuse, (physical or sexual) than age matched controls. 142

The brain can actually be remodeled to be less efficient at restoring homeostasis. Demonstration that women with chronic vulvar pain have differences in their brain anatomy compared to age matched controls supports the concept of the brain as an important modulator of pain in women with vulvodynia. 143 In chronic pain patients, a tendency to focus on pain (attentional bias) increases pain, disability and distractibility.144

Altered levels of stress hormones and other neurotransmitters affect our thoughts, actions and emotions. 145 Catastrophizing refers to predicting negative outcomes and assuming that the negative outcome will be catastrophic. Catastrophizing is associated with depression and anxiety, two significant predictors of vestibular pain in postmenopausal women with painful intercourse. Estrogen levels were not predictive. 146

The majority of women with provoked vulvar pain are highly stressed.147148 Stress is under consideration as an important etiologic factor in vulvar pain149 since, in the rodent, it actually alters the brain through microglial proliferation in the hippocampus and substantial nigra,150 the same areas that show increased gray matter density inwoven with provoked vulvodynia compared to controls.151 The gray matter density was related to the women’s clinical symptoms as measured by their pain thresholds at the introitus. Rosemary Basson’s model in Figure 2 depicts the increased allostatic load resulting from the build-up from stress to pain sensitization, sexual dysfunction, and further stress.

Figure 2: Circular model of provoked vestibulodynia 152


Figure 2: Circular model of provoked vestibulodynia to illustrate the compounding effects of subsequent sexual dysfunction on overall allostatic load: emotional distress associated with premorbid anxiety, depression, traits of catastrophization, harm avoidance, hyper-vigilance, self-dislike, perfectionism may be associated with neuroplastic changes in the central nervous system leading to central sensitization and pain amplification. Feelings of being sexually substandard compound the etiological factors and lessen sexual motivation and response. Pain-induced cognitive changes may impair processing of sexual stimuli generally and at the time of sexual activity. Motivational changes associated with chronic pain circuitry may further impair sexual motivation. Stress responses of body and skin add t0 the skin pathophysiology.

Resilience describes a healthy body able to rebound from stress and disease. A number of attitudes and behaviors have been shown to strengthen the body’s ability to sustain or restore resilience and buffer against allostatic load. Acceptance, optimism, humor, cognitive flexibililty, religion/spirituality, altruism, social support, moderate physical activity/exercise are among them.153 These skills can be learned and are recognized as making a difference in people’s lives.154

Emerging research of two psychological therapies, Cognitive Behavioral Therapy (CBT) and mindfulness, suggests benefit to both pain and to sexual dysfunction.155 Control of pain to eliminate its negative reinforcement on sexual function is a logical first step.

Waning pain theories


Use of a low oxalate diet with calcium citrate to bind oxalate excreted in the urine gained attention based on a single case of vulvodynia successfully treated with the protocol.156 Subsequent studies provided no validation.157 158 Currently, there is no justification for evaluation and treatment of hyperoxaluria in women with vulvodynia due to its low yield and economic burden.159 It is important to recognize that some of the foods high in oxalates are similar to foods to be eliminated as bladder irritants. There may be value in a trial of eliminating known bladder irritants in women who report urinary symptoms as part of their pain. These include foods high in acidity (tomatoes, alcohol, or foods with citric acid), chocolate, caffeine, artificial sweeteners, and spices.160

Human papilloma virus (HPV)

There is now  little support for the idea that HPV might be related to vulvodynia. In 135 cases compared with 322 controls without pain: HPV DNA was found in 29.6% cases and 23.9% controls (RR1.4; 95% confidence interval).161 Treatment for warts with topical medication or surgical excision, however, may be a source of pain.

Pruritus in relation to vulvovaginal disorders

We now know that the sensation of itch and nociception cannot be equated with each other. The once popular theories that itch is based on a specific pattern of action potentials running through pain pathways or that itch results from the combination of other primary sensory signals, have now fallen out of favor.162 The confirmation of long-denied existence of central itch-specific neuronal pathways in the human supports the concept that the sensation of itch and nociception represent distinct sensory systems.163 164 165

  • 1 – Pruriceptive pruritus involving stimulation of the free nerve endings of a subset of nociceptive C-fibers in the skin. The sensation is transmitted to the dorsal horn of the spinal cord, then up the spinothalamic tract to the cerebral cortex for processing.
  • 2 – Neuropathic pruritus, cased by damage of the itch-transmitting afferents of the peripheral nerves or the spinal cord, e.g., postherpetic pruritus.
  • 3 – Neurogenic pruritus, arising because of disease of central structures of the CNS such as brain tumors or abscesses.
  • 4 – Psychogenic pruritus based on metabolic disorders in the CNS. Type 1 is the type involved in inflamed skin.

In the skin, many factors contribute to the induction, exacerbation, or suppression of pruritus. Physical stimuli such as heat and cold modulate the perception of itch; painful heat and cold can significantly diminish it, whereas moderate cold intensifies itching.166 Mechanical factors such as rubbing or scratching can briefly suppress itch by activating nerve fibers that selectively activate and de-activate brain centers.167 The most important factors, however, are mediators that directly induce itch by binding to pruriceptors or, indirectly, by releasing products that induce other cells to release pruritogenic substances: e.g., histamine from mast cells, interleukin-31 from T cells, or nerve growth factor from eosinophils and keratinocytes.168

Both the peripheral and central nervous systems play an important role in the perpetuation of itching. A number of inflammatory mediators directly activate pruritus-mediating nerve fibers, and some of these mediators can also produce long-term changes in the skin. For example, significantly elevated levels of Nerve Growth Factor and Substance P cause increase in cutaneous itch fibers, adding to the intensity and chronicity of the pruritus.169

Vulvovaginal pain related to a specific disorder

The most common areas of the vulva involved with pain include: discomfort with separation of the labia minora, dyspareunia from pain on penetration through the vestibule, and point tenderness localized to area surrounding the Skene gland orifices or the Bartholin gland openings within the vulvar vestibule.170

The manifestations and symptoms of each of the conditions in Table K-1 are described under the annotation indicated by the letter in parentheses. Diagnosis of each condition is included in the annotation.

Each known cause of vulvovaginal pain has its unique constellation of clinical manifestations. Pattern recognition is key: training the ear to listen for a history of irritative vaginal secretions, dyspareunia, or pain suggesting one of these categories, and training the eye to detect the presence of architectural abnormalities or epithelial lesions of the vulva or vagina are the challenges of vulvovaginal diagnosis.

Generalized vulvodynia: symptoms

Generalized vulvodynia refers to burning, stinging, soreness, pain, irritation, or rawness anywhere on the vulva, perineum, or peri-rectal area. It is usually sudden in onset, and can occur at any age. It may be provoked (brought on by touch, movement, sexual activity) or spontaneous (spontaneous, without any obvious trigger), or a combination of both (mixed). The pain may be constant or sporadic, present for hours, days, weeks, then regressing. It may be diffuse without clear borders, or focal, or may alternate in location. Women seldom use the word vulvodynia, or even the word pain; instead they describe burning, stinging, soreness, and irritation. They often have trouble localizing the site and explaining what they feel. They use various descriptors for the sensations:

“Deep aching”

“Feels like sand paper”

“Feels like my pubic hair is being pulled”

“Rawness, “rug burn”

“Sitting on a cactus”

“Tennis ball wedged in the vagina”

“Feels like there are insects crawling underneath the skin”

“Zapping, shooting” (paresthesias)

“Constant awareness of vulva, vagina”

Women often describe urinary symptoms such as burning, frequency and urgency but urine cultures are negative.

Any pressure stimulus on the vulva can worsen the pain: tampon insertion, sexual intercourse, speculum insertion, tight clothing, biking, horseback riding, sitting, walking, and exercising.

Localized vulvodynia: symptoms

Women often give clues that they may have localized provoked pain. Pain often starts out as being provoked, but persists as spontaneous or both provoked and spontaneous pain.

“Intercourse has never been comfortable for me” or “Recently it started to hurt”

“I have never used tampons because they hurt” or “Lately I can’t use tampons”

“I’m just too small.” or “My partner is too large.”

“You must use your smallest speculum” or “I have always had a problem with the speculum.”

“I keep having infection- yeast, BV, yeast, BV”

A recent study aimed to determine whether there are differences in the clinical presentation of symptoms and vulvar pain ratings in postmenopausal women compared with premenopausal women with provoked vestibulodynia (PVD) enrolled in a clinical trial, after correcting for estrogen deficiency. Researchers found that pre-and postmenopausal women with PVD have similar pain scores, and with the exception of a higher incidence of burning in postmenopausal women, similar presenting clinical symptoms. The statistical power of the study was limited by the small number of postmenopausal women in it. 171


Pudendal neuralgia: symptoms

Pain occurs over the sensory distribution course of the pudendal nerve: in the vagina, vulva, labia, mons, and clitoris. Symptoms of pain and paresthesia may extend as far as the groin, inner leg, buttocks, and abdomen.172 The pain and paresthesia may be perceived in only one of these areas, in several, or in all of them, and the pain may vary in location from time to time. It often starts in one place and progresses; usually it is unilateral. The symptoms may, however, be bilateral or worse on one side than the other.

The varied presentation of PN may reflect the nerve’s mixed functions (motor, sensory, autonomic) and its multiple branches with anatomic variations.173

Patients report beginning the day in relative comfort, with pain increasing gradually over the day. Sitting significantly exacerbates the pain. By day’s end they are often miserable; falling asleep may be difficult. Although they awaken in the night for another reason, the pain itself does not disturb sleep.174 Sitting on the toilet seat often brings some relief by lessening the pressure on the nerve. Extreme sensitivity to light touch (hyperesthesia) restricts clothing to none at home and loose pants and skirts when out. Constipation, often exacerbating pain after bowel movement,175 urinary frequency, urgency or hesitancy,176 and vulvar, perineal or rectal pain during or after intercourse,177 are all associated.

A typical case begins with remissions and relapses, evolving to a chronic and progressive course,178 completely disruptive of day-to-day living, relationships, and sexual function.

Generalized spontaneous vulvodynia: work up

A full work up is necessary to determine if the source of these descriptions comes from any of the conditions in Table K-1 and is therefore pain related to a specific disorder. Pain mapping (Annotation I: Pain and symptom mapping and the Q-tip test) will identify the involved areas. In the case of generalized vulvodynia, there will be no other physical findings other than possible erythema. The combination of the history, the pain map showing generalized distribution, and the lack of any findings to suggest a known disorder (this may require more than one visit), leads to the diagnosis of generalized spontaneous vulvodynia. Remember that there may be more than one problem. Pain located in a different location from the area affected by infection or dermatosis, may suggest vulvodynia in addition to the vulvar pain from the infection or dermatosis. For example, a woman with multiple, pruritic syringomas of the labia majora also has spontaneous burning in the vestibule from vulvodynia. Whether the two problems are related is still unclear.

Localized provoked vulvodynia: work up

Friedrich’s criteria 179 have traditionally been used for diagnosis of localized provoked vulvodynia:

Severe pain on vestibular touch (Q-tip test) or attempted vaginal entry

Tenderness to pressure localized within the vulvar vestibule

Physical findings confined to vulvar erythema of various degrees.

However, since localized vulvodynia may also be spontaneous, these criteria are now only partially accurate. As with generalized vulvodynia, a full work up is necessary to determine if the source of these descriptions comes from any of the conditions in Table K-1 and is, therefore, pain related to a specific disorder. Localized pain in the vestibule may be the first condition that comes to mind, but scarring from undiagnosed lichen sclerosus (Atlas of Vulvar Disorders), chronic inflammation from inflammatory vaginitis (Annotation O: the vaginal epithelium), or burning from the innumerable causes of pelvic floor hypertonicity (Annotation L: the pelvic floor) reflected in the vestibule, are a few of the possibilities. It is important to note that the presenting symptoms of lichen planus are soreness and burning. Classic erosions and reticules are not always seen. Primary or secondary vaginismus (Annotation D: patient tolerance for exam) (Pelvic floor dysfunction/vaginismus)may also be involved.

In the absence of any spontaneous discomfort, and with tenderness to pressure and touch (Q-tip test) in a focal area (often the vestibule) without identification of any known cause, localized provoked vulvodynia is diagnosed.

Pudendal neuralgia: work up

The diagnosis of PN is a clinical diagnosis of exclusion after ruling out other causes of symptoms (Table K-1). Clinical diagnostic criteria for PN developed by a multidisciplinary working party which met in Nantes, France in September, 2006 (Nantes criteria180) include five essentials:

(1) pain along the anatomical distribution of the pudendal nerve;
(2) pain aggravated by sitting;
(3) the patient is not awakened at night by the pain;
(4) there is no objective sensory loss on clinical examination; and
(5) the pain is improved by an anesthetic pudendal nerve block.

Physical examination is usually normal. The most constant element on physical examination is a replication or worsening of the pain during rectal or vaginal digital pressure in the area of the ischial spine.181 Although this may occur in an asymptomatic woman, unilateral tenderness in this location suggests PN by the Nantes criteria.182

Clinical neurophysiology tests have low diagnostic efficacy and must be considered to only be complementary investigations. Nerve response time that is slower than normal (<2.2 ms) by pudendal nerve motor latency testing (PNMLT) may183 indicate nerve damage but is not considered a highly sensitive test. PNMLT tests only motor function; currently no modality exists for sensory testing of the pudendal nerve.

Differential diagnosis includes the specific causes of pain in (Table K-1), tumor in any location impinging on the pudendal, ilioinguinal or genitofemoral nerves, diabetic neuropathy, viral infection (herpes simplex, herpes zoster, HIV), multiple sclerosis, and pathology of the spine. Tarlov cysts are meningeal cysts located in the sacral region. These cysts are usually considered incidental findings on MRI, but may cause sciatica or perineal pain resembling pudendal neuralgia. Some studies suggest that up to 50% of patients with Tarlov cysts may have perineal pain.184 Symptomatic Tarlov cysts should correlate with the location of pain.


Vulvar pain from a known disorder often resolves with treatment or control of the condition, but in some cases, treatment of the pain is necessary in addition to treatment of the disorder. Currently there is no standardized treatment for vulvodynia. A systematic literature search concluded that comparison of clinical trial results in vulvodynia is not possible because of a lack of standard treatment outcome measures. The authors recommended application of the IMMPACT criteria to guide the development of a minimum core set of standard outcome measures.185

A review of the available clinical therapies for vulvodynia management also revealed new data implicating pro-inflammatory mediators pain elicitation. The authors emphasize that acceptance of inflammation as a possible contributing factor to the occurrence of vulvodynia opens a new view of possibilities for treatment and management with the use of agents to block pro-inflammatory mediator production.186.

Approach to the patient

Vulvar pain from a known disorder, as stated above, may resolve with treatment or control of the condition, but in some cases, treatment of the pain is necessary in addition to treatment of the disorder. Vulvodynia, by definition, pain of unknown cause, has no standardized treatment and definitely no one-size-fits-all treatment. Well-conducted studies of vulvovaginal pain of any type are few, and the level of evidence is low. Randomized controlled studies are rare, whereas case-control studies and clinical observations are common.187 Faced with debilitating problems, clinicians work with available information and reliance on clinical experience, sometimes despite current study information. As one expert expresses, “They (the tricyclic antidepressants) are extremely useful in managing the neuropathic component of vulvar pain. Despite a recent, apparently well-conducted study showing lack of benefit, my 25 years of personal clinical experience with tricyclics convince me that I should wait for follow-up studies before abandoning this therapy.”188

Patients with any chronic pain are often frustrated and anxious. Vulvar pain and vulvodynia, with their impact on a woman’s femininity and sexual function ( Vulvar pain and sexuality), are no exception. Women with vulvar pain and vulvodynia have failed many treatments and have seen many physicians.189 They need to be reassured that their symptoms are real, and that treatment is available for this complex set of disorders.190 Treatment must be individualized. Women, and their partners, also need to understand that there is no single modality to “fix” the problem; often, it is the combination of a variety of approaches that brings amelioration. A multidisciplinary team approach is needed to address the different components of each case. Most patients need a combination of psychosexual, pharmacologic, and rehabilitative/physiotherapy-based interventions with guidance from a team that may include gynecology, physiotherapy, clinical psychology, sexual counseling, and pain specialists.191 Treatment choices must include involvement of the partner when appropriate, consideration of the local health care system, and attention to cost.192

A precise timeline is not possible, and progress is slow. A woman needs a week or two (often having increased slowly over a week or two prior to that) at the therapeutic level of any medication. She may say that there is no difference, but close questioning may reveal, for example, that her pain level has gone from 7/10 to 6/10 most days. She may have had a day or two free of pain. Or, she may notice that a pain flare lasts a shorter duration. Quantified information is essential in order to see the picture and continue a potentially helpful medication. At each visit, obtain a quantified number (0-10), for highest pain level and number of days that this level exists each month. (Annotation I: Pain mapping and the Q-tip test).


Identify and eliminate any possible pain triggers
Educate about vulvar pain

Use handouts (to patient handouts), website referrals, and local support groups. Emphasize that pain may need to be managed, not cured. Describe the typical slow and gradual regression of pain that may occur. Discuss global impact on every aspect of sexuality (Vulvar pain and sexuality), emphasizing that pain must be managed first; then work on sexual function can occur. Discuss the psychology of pain, factors that worsen pain, and the importance of taking charge. Suggest Margaret Caudill’s How to Manage Pain Before It Manages You, 3rd edition. New York, Guilford Press, 2009. Offer counseling for support, anxiety, depression, or relationship problems.

Provide information about comfort measures

Flares of pain can be minimized by a variety of factors (Self Help Tips for Vulvar Skin Care: By far, the most important comfort measure is the technique of “Soak and Seal:” sitting in comfortable water (tub, sitz bath under the toilet seat, or gentle hand held shower for 5-10 minutes twice daily). A woman who is physically unable to use the tub or sitz bath may protect the bed with plastic sheeting and use sopping wet compresses. Pat dry gently; then seal in the moisture with a film of petrolatum or mineral oil. Cool gel  packs wrapped in a soft cloth are also important to pain management. Although ice against the skin can cause frostbite, pain is significantly allayed by cold packs.

Set expectations

While the symptoms of vulvodynia may remit entirely, it is possible that they improve but do not disappear; they are managed, not cured. This is an important concept to emphasize at the initiation of therapy. There is no crystal clear cure, no magic bullet, no one-size-fits-all approach. There is improvement with time and effort.

Provide guidelines for sex

We ask women who have pain on penetration to stop vaginal intercourse until there has been some improvement in symptoms. Ongoing intercourse in the presence of pain is a negative reinforcer and can lead to secondary vaginismus. (Annotation D: Patient tolerance for genital exam). We encourage open communication between a woman and her partner about her pain with the effort to prevent feelings of rejection. We encourage intimacy and the pursuit of any mutually agreed upon pain-free alternatives to vaginal intercourse.

If sexual intercourse is possible with a level of comfort acceptable to the woman, we recommend use of a lubricant such as a few drops of plain baby oil without fragrance; this may be well tolerated as long as condoms are not being used. Latex condoms are not compatible with oil-based lubricants or medications. In women using condoms, a water-based lubricant is appropriate (e.g., an iso-osmotic, pH balanced product, e.g., Pre-Seed®). Some women find a decrease in sexual pain with use of side-lying or rear entry.

Pharmacologic treatment for vulvodynia

Topical medications: antinociceptive agents

Topical Lidocaine was previously recommended as a firstline treatment for vulvodynia based on promising results in uncontrolled trials.193 194 and in one controlled trial.195  It was no better than placebo in another.196  Since women anecdotally report that lidocaine is helpful, and given that  studies have been small, further placebo-controlled studies should be conducted before firmly recommending against lidocaine.197

Women with generalized vulvodynia or vulvar pain from a known cause often benefit from lidocaine during pain or itching flares. In some cases where sexual intercourse is painful, we ask a woman to apply one teaspoon to the vestibule 10-15 minutes prior to intercourse, avoiding the clitoral area. After 15 minutes, any excess is wiped away so that it does not come in contact with her partner. Lubrication can then be added. (section on lubricants, Annotation P: Vaginal secretions, pH, microscopy, and cultures). Prior to Pap smear, colposcopy, or other procedures, the same Lidocaine application is helpful. We always ask a woman to use Lidocaine with dilators or with physical therapy treatments, if acceptable to the therapist. (Annotation D: Patient tolerance of the genital exam). Women should be warned that Lidocaine may burn on initial application, the sensation lasting about 45 – 60 seconds, before numbing takes effect. This burning, as long as it stops after the first 60 seconds, is not harmful. Lidocaine is sometimes prescribed in 2% gel form. Since this contains alcohols, it often burns more than the ointment form. Lidocaine 2.5%-prilocaine 2.5% ointment combines two amide topical anesthetics; it provides more anesthetic relief especially in the vestibule, but may cause more burning as it takes effect. Keeping the lidocaine in the refrigerator so that it is chilled can be helpful. Lidocaine ointment 5% has 50 milligrams of lidocaine in 1 gram. Use of local lidocaine should not exceed 5 g of Lidocaine Ointment USP per day, 5% containing 250 mg of lidocaine base (equivalent chemically to approximately 300 mg of Lidocaine hydrochloride). This is roughly equivalent to squeezing a six (6) inch length of ointment from the tube. In a 70 kg adult, this dose equals 3.6 mg/kg (1.6 mg/lb) lidocaine base.

A small study reports early clinical observations on the use of combination topical meloxicam 0.3% and lidocaine 5% applied to the vulva twice daily by patients with vulvodynia. Of the eight participants, six had a subjective improvement in their symptoms with the use of the combination gel. They reported between one- and four-point reductions on the Likert pain scale and mild to moderate improvement of symptoms. Common side effects reported were burning and stinging.198

Other topical therapies with questionable efficacy include estrogen,199moisturizers, topical muscle relaxers,200 capsaicin,201 202

Topical tricyclic antidepressants and anticonvulsants have been reported helpful but studies are small, requiring further investigation.203204

Oral medications

In general, improvement with any centrally acting drug takes weeks and is uneven. Pain may seem to lessen but then return; expect a trend of slow diminution of pain, with less frequent and less intense flares.

The medications used for pain management have a number of side effects and interactions. Patient education is essential, especially in view of the fact that an unexpected side effect e.g., burning with Lidocaine or sedation with tricyclic may cause rejection of medications that could otherwise be helpful.


Antidepressants such as amitriptyline, nortriptyline and desipramine, not only target pain and depression (associated with vulvodynia),205206but also have proven neuropathic pain-relieving effects.207

The mechanism of action of tricyclics has been thought to be related to inhibition of the re-uptake of transmitters– specifically nor-epinephrine and serotonin. It is possible that the mechanism may be more closely related to anticholinergic effects. Tricyclics affect sodium channels and the N-methyl-d-aspartate (NMDA) receptor.208

Tricyclic antidepressants (amitryptiline, nortryptiline, desipramine) are  considered effective compounds in the treatment of neuropathic pain, fibromyalgia, low back pain, and headaches according to meta-analyses and clinical studies of these agents retrieved through the use of MEDLINE, Google scholar, and Cochrane databases.209 They are a common treatment for vulvodynia.

In randomized, prospective trial, 76 women with generalized, localized or mixed vulvodynia undertook one of three treatment interventions for a period of 12 weeks: self-management, oral amitriptyline (10–20 mg/day), or topical triamcinolone plus oral amitriptyline (10–20 mg/day). The trial suggests that self-management has a modest effect and that low-dose amitriptyline (with and without topical triamcinolone) is not effective in reducing pain in women with vulvodynia.210

Studies with higher doses of amitriptyline (40-60 mg/day) suggested that 50% or greater improvement in pain scores can be achieved for both provoked and spontaneous vulvodynia.211 Because it has been thought that doses lower than those used to treat depression could be used for pain, inadequate dosage may be a major flaw in treatment and treatment studies of tricyclics.

Emphasize to patients that tricyclics are being used for pain, not depression, although the anti-depressant effects may be useful.

Begin treatment with the less sedating nortriptyline or desipramine: 10 mg at bedtime and increase the dose by 10 mg every five days to 50 mg at bedtime. If the patient is extremely sensitive to medications, nortriptyline syrup (10 mg/tsp) can be used to help the patient acclimate to the drug side effects with small increments of dose. Patients over 65 years of age also need slower (weekly) increases. If the patient is tolerating the side effects, the dose should be slowly increased to a total maximum dose of 100 to 150 mg per day. Common reasons for treatment failure are inadequate dosage or a short duration of therapy since it takes weeks to observe an effect. We explain that the pain did not evolve overnight and is not going to disappear quickly. A tricyclic with dosage of 100 to 150 mg for three months without improvement would prompt us to move to another agent.

Both nortriptyline and desipramine are less sedating than amitriptyline and have fewer anticholinergic side effects (dry mouth, constipation, sweating, palpitations). Sedation is often transient and improves with time on the medication. Constipation is a common problem and needs proactive management to prevent rejection of the drug by the patient for this reason. A patient with irritable bowel syndrome manifested as constipation may tolerate tricyclics poorly without aggressive management: use of fiber supplements, docusate, or senna. Mild vertigo and palpitations are common. An electrocardiogram should be obtained in women over 50 years of age and should be normal prior to initiating therapy. If it is abnormal, or if the woman has a history of a cardiac arrhythmia, we suggest consultation with the patient’s primary care provider or a cardiologist. Sun sensitization can occur.

Checking with the glaucoma patient’s ophthalmologist prior to prescribing a tricyclic is also recommended.


Antidepressants, such as serotonin reuptake inhibitors, are largely ineffective for vulvodynia.212

Neuromodulating Agents


Gabapentin (Neurontin), is FDA approved for the treatment of the neuropathic pain of post-herpetic neuralgia. It is a gamma aminobutyric acid (GABA) analogue, which was synthesized to mimic this neurotransmitter. Gabapentin binds to the α2δ subunit of voltage-dependent calcium channels in the central nervous system. It has been proven that gabapentin halts the formation of new synapses, therefore decreasing neuropathic pain.213
Successful use of gabapentin for generalized vulvodynia was initially reported.214 In another study of 152 women with generalized spontaneous vulvodynia treated with gabapentin, (64 percent) achieved resolution of at least 80 percent of their symptoms.215 These studies were not, however, considered sufficient evidence of efficacy.216

Gabapentin in the treatment of vulvodynia in a randomized controlled trial was not more effective than placebo on the primary outcome measure, the tampon test (a surrogate marker for dyspareunia), or on secondary outcomes: sexual intercourse pain and daily pain. A lack of gabapentin treatment effect over placebo is consistent with previous controlled studies investigating other pharmacologic treatments for vulvodynia.217

Other studies have examined the use of pregabalin,218  lamotrigine,219 and carbamazepine,220 but more rigorous RCTs are needed before treatment recommendations can be made.

Other medications studied for vulvodynia treatment


In the only randomized clinical trial with placebo group, Bornstein, et al examined the efficacy of fluconazole for provoked vulvodynia. After a six month regimen of 150 mg per week there was no significant difference between the treatment group (15% success rate) and the placebo group (30% success rate).221

Other oral medications not studied for vulvodynia


Intravaginal diazepam suppositories as an adjunctive treatment for high-tone pelvic floor dysfunction and sexual pain have given significant clinical improvement in one report.222  5-10 mg ia prescribed in a compounded vaginal suppository nightly for 30 days, with titration of dosing frequency at successive visits as pelvic floor physical therapy progresses. It is possible to insert a diazepam 10 mg tablet vaginally although some women have difficulty retaining the tablet. There are reports of a blue green discoloration of vaginal secretions after local diazepam. Vaginal valium can be less sedating than oral valium; if sedation occurs, the dose can be lowered to 2.5 mg. The potential for habituation with vaginal diazepam is unknown; patients need to understand that habituation may occur.A double blind randomized placebo controlled trial evaluated the effectiveness of vaginal diazepam in addition to transcutaneous electrical nerve stimulation (TENS) in the treatment of vestibulodynia. Decreased visual analogue pain scores were not statistically significant. Vestibular nerve fiber current perception threshold for all of the nerve fibers increased after the treatment, but this increase was significant in the diazepam group only for the values at a 5-Hz stimulation (C fibers) with a change of 47.8% vs 26.9% (p<0.05).

Nonsteroidal anti-inflammatory drugs (NSAIDs)

NSAIDs have not been adequately studied for vulvodynia; they are widely anecdotally reported to be ineffective. In one study of provoked vulvodynia, the observed low expression of cyclooxygenase 2(COX 2) and inducible nitric oxide synthetase (iNOS)223 suggests that NSAIDs would not be helpful.


Corticosteroids have strong anti-inflammatory effects by reducing the production of interleukin-beta, which researchers have found elevated in the hymeneal tissue of women with vulvodynia.224 Smaller and likely underpowered RCT’s using high potency topical steroids have shown negligible effects.225 226 Some  success has been noted in case reports and series using combined local subcutaneous infiltration of lidocaine and a steroid (methylprednisolone or beta methadone) to the vestibule.227 228  In a large RCT, researchers randomly assigned women to topical hydrocortisone 1% twice daily or group CBT of 12 sessions. Both groups showed a significant improvement in pain and sexual functioning post-treatment, but effects were larger among the women in the CBT group. 229 Again, more randomized study on both topical and injectable steroids is needed.


Opioids have shown consistent efficacy in neuropathic pain,230 and patients with nociceptive pain syndromes may also require opioid therapy if they do not respond to nonopioid analgesics, or if their pain is severe at the outset.231 Use of opioids has not been well studied for vulvodynia. We have found that it is helpful to use over the short-term an opioid, such as acetaminophen with codeine, 625/30 every 4-6 hours while awaiting the efficacy of a longer acting medication, such as one of the tricyclic antidepressants. Proactive management of constipation is essential.


Tramadol (Ultram™) inhibits the reuptake of serotonin and norepinephrine and may provide analgesia through this mechanism. Systematic reviews found that tramadol was effective for relief of neuropathic pain232 and pain in patients with fibromyalgia.233

The dose is 50-100 mg by mouth every 4-6 hours not to exceed 400 mg/day.

Tramadol has similar side effects of other weak opioids, although the incidence of gastric upset may be higher. Seizures are an additional risk, particularly in patients who take antidepressants, neuroleptics, or other drugs that decrease the seizure threshold. Tramadol has been associated with increased risk for suicide,234 and must be used with caution in patients who have emotional disturbance, suicidal ideation or attempts in the past, or are addiction-prone. Although tramadol is not scheduled as a controlled substance, dependence has been reported.235

Non-pharmacologic treatment for vulvodynia


Female mice were sensitized to the hapten dinitrofluorobenzene (DNFB) dissolved in saline on their flanks, and subsequently challenged with the same hapten or saline vehicle alone for ten consecutive days either on labial skin or in the vaginal canal. The study evaluated tactile ano-genital sensitivity, and tissue inflammation at serial timepoints. DNFB-challenged mice developed significant, persistent tactile sensitivity. Allergic sites showed mast cell accumulation, infiltration of resident memory CD8+CD103+ T cells, early, localized increases in eosinophils and neutrophils, and sustained elevation of serum Immunoglobulin E (IgE). Therapeutic intra-vaginal administration of Δ9-tetrahydrocannabinol (THC) reduced mast cell accumulation and tactile sensitivity. Mast cell-targeted therapeutic strategies may therefore provide new ways to manage and treat vulvar pain potentially instigated by repeated allergenic exposures.236


Most of the available studies are limited by their design: lack of a control group, lack of randomization, inadequate, short-term follow up, small series. Most studies are industry sponsored. Histological  evidence is commonly reported as proof of tissue regeneration after LASER treatment. However, the histological changes noted can also be consistent with reparative changes after a thermal injury rather than necessarily representing regeneration or restoration of function.237 Recently published studies regarding the efficacy of LASER therapy in the treatment of vulvodynia are few in number and suggest limited efficacy. A retrospective study indicated less pain with sexual intercourse among  24 of 37 women, but 35% of the patients required vestibulectomy to control pain symptoms.238 A 2016 study of 70 women who underwent fractional micro-ablative CO2 LASER for vestibular pain and vestibulodynia or menopausal symptoms secondary to GSM/VVA showed statistically significant improvement in dyspareunia and pain scores, but there was no statistically difference in outcomes between the study groups.239 A 2017 double blind, randomized,  placebo controlled study of 34 women treated with low-level LASER therapy versus placebo showed clinical pain improvement in 78% of the LASER group as well as 44% in the placebo group. But Q-tip test, intercourse pain on the Visual Analog Scale, and tampon tests before and after treatment, severity of discomfort in daily activities and/or in daily pain intensity did not show a difference between groups.240 The ICS/ISSVD Best Practice Consensus Document of 2019 therefore does not recommend LASER for routine treatment of vulvodynia unless part of a well-designed clinical trial or with special arrangements for clinical governance, consent and audit.241

Injections and blocks

Botulinum Toxin

One treatment for pain with possible effects on central sensitization is botulinum toxin (BoNT).242.

In muscle, BoNT blocks acetylcholine release from presynaptic neurons at the nicotinic neuromuscular junction. The mechanism in pain likely relates to its ability to similarly block the release of pain-associated pro-inflammatory neurochemicals, including glutamate, CGRP, and substance P. Thus, when applied to chronic pelvic pain, BoNT may not only target peripheral sources of pain such as pelvic floor muscle spasm, but may also reduce peripheral and central sensitization.243

BoNT injections have been used for both provoked and spontaneous pain, injected into the vestibule and/or pelvic floor muscles to reduce hypertonicity. Initially a few case reports and small series suggested that the modality was beneficial.

Doubt arose from a randomized, double blinded, placebo controlled study injection of 20 I.E. Botox in the bulbospongiosis muscles of women diagnosed with vestibulodynia that did not reduce pain, improve sexual functioning, or impact the quality of life compared to placebo, evaluated at 3 and 6 months follow up. In a systematic review, there was fair evidence of a lack of efficacy for botulium toxin injections for localized provoked vulvodynia.244 For generalized vulvodynia there was insufficient evidence in a case report,245 and a study of a small number of women.246

Higher doses of the toxin appear to have brought greater success. In a randomized, double-blinded, placebo-controlled trial, injection of botulinum toxin type A 80 units into the pelvic floor muscles has been shown to be more effective than placebo at reducing pain and pelvic floor pressure in women with chronic pain and muscle spasm.247  A retrospective cohort study of all women with intralevator Botox injection (100-300 Units) at a Boston hospital from 2005 through 2010  demonstrated effectiveness in 79.3% of women with refractory myofascial pelvic pain with few, self-limiting adverse effects.248

The growing body of literature on the use of BoNT to treat vaginismus, vulvodynia and chronic pelvic pain consists largely of case reports, case series, and uncontrolled trials. A recent review of BoNT literature by investigators at the National Institute of Health was performed for methodological details to aid the development of a consistent procedure for clinical treatment. The reports are overwhelmingly positive.249

Four brands of toxins are currently FDA-approved in the USA for various indications. OnabotulinumtoxinA (onaBoNTA: Botox; Allergan, Irvine, CA, USA), abobotulinumtoxinA (aboBoNTA: Dysport; Ipsen Pharmaceuticals, Basking Ridge, NJ, USA), and incobotulinumtoxinA (incoBoNTA: Xeomin; Merz Pharmaceuticals, Frankfurt, Germany) are serotype A toxins. RimabotulinumtoxinB (rimaBoNTB: Myobloc; Solstice Neurosciences, South San Francisco, CA, USA) is serotype B. BoNT dosing is based on Bunits,^ (1 Unit = LD50 for mouse intraperitoneal injection). Owing to differences in manufacturing, each brand is dosed differently.

Doses varied widely within each brand. OnaBoNTA doses ranged from 10 to 300 U and aboBoNTA doses from 20-500 U. The single study using incoBoNTA provided individualized doses between 100 and 400 U, whereas that reporting rimaBoNTB used 2,500 U. The onaBoNTA doses for chronic pelvic pain tended to be higher than those for vaginismus and vulvar pain disorders.250. Studies were included if they described injection in to the pelvic floor muscles, not into superficial perineal muscles.

Different localization techniques ranging from none or palpation only, electromyography electrical stimulation with or with our ultrasound, fluoroscopy and/or CT scanning were used to guide or confirm needle placement in muscle.

Analgesia and sedation included none or no mention of it, general anesthesia, conscious sedation alone, or with a topical or local anesthetic. A topical agent was used alone in one study; in another local intramuscular anesthesia was used before injection and the procedure was followed by a pudendal nerve block. In one study, a pudendal nerve block was placed before toxin injection. In 2 groups, BoNT injection was followed by bupivacaine injection to the same muscles.

The NIH study supports the safety and tolerability of BoNT injection into the muscles of the pelvic floor in women. Although the lack of complete and essential information in published reports does not allow for recommendations for a single best practice methodology, the reports illustrate that lower doses were associated with fewer bowel and bladder adverse effects, and emphasize the importance of a needle guidance technique in addition to use of anatomical landmarks, and the tolerability of injection in the office setting. The currently published reports routinely omitted information critical to assessment of the technical approach, efficacy, and side effects, such as data on the type/brand of toxin and doses used, muscle selection, guidance techniques used for accurate needle placement, and outcome data. Researchers and clinicians will benefit from inclusion of these data in future publications.251.


Success with injections of steroid/lidocaine has been reported in localized, provoked vulvodynia.252 253

In the largest RCT (N = 97) Bergeron et al. randomly assigned women to topical hydrocortisone 1% (twice daily) or group CBT (12 sessions). Both groups showed a significant improvement in pain and sexual functioning post-treatment, but effects were larger among those in the CBT group.254

At this time, more controlled studies are needed before corticosteroids (either topical or injections) are recommended for treatment of vulvodynia.255


Interferon injections, both intralesional and intramuscular, appeared hopeful for localized provoked vulvodynia in the past,256 257 but are not in widespread use at present. A recent review suggests that Interferon treatment may be considered for women with vulvodynia and histologic findings suggestive of HPV infection, if other treatments have failed.258

Serial nerve blocks

An observational study including 27 women reported that serial nerve blocks (combination of caudal, epidural, pudendal, and local infiltration) significantly improved vestibular pain. Follow-up, however, was limited to 8 to 12 weeks.259 Pudendal and spinal nerve blocks have been used for diagnosis and management of generalized vulvodynia. Guided image blocks are preferred to support or rule out the diagnosis since failure of traditionally performed pudendal nerve block in labor may be due to operator error and not necessarily the absence of PN. To date, evidence is limited to small studies.

Since the autonomic sympathetic nervous system conveys nociceptive messages from viscera to the brain, interventions with the sympathetic system are being used for perineal pain management. Ganglion impar blocks, steroid injection around the terminal branch of the sympathetic chain in the presacral space, have been performed with good results for generalized vulvodynia.260 Hypogastric plexus and L2 lumbar sympathetic blocks are being investigated.

Pudendal nerve blocks are both diagnostic and therapeutic. Good evidence is lacking, but the block has been shown of value in small studies. In a group of 26 women a series of five CT-guided blocks at the ischial spine over a five month period yielded a 62% reduction in pain.261 In a prospective study of 55 patients, 87% had good to excellent outcomes.262 In a recent study by Fannuci et al.,263 27 patients with pudendal neuralgia underwent CT guided pudendal nerve blocks. At 1-year follow-up, 92% showed continued clinical improvement.

For spontaneous pain unresponsive to medical management, evaluation for entrapment of the pudendal nerve may be pursued.264 The nerve may be tested for delays in conduction; if abnormality is present, successful relief of pain by pudendal block may lead to surgery to release entrapment. There are four described approaches to surgical decompression of the pudendal nerve. All surgical methods involve neurolysis to eliminate the possible source of compression. The trans-gluteal approach is currently the most common and successful approach for pudendal neurolysis.265 This procedure was originally described by Professor Roger Robert from Centre Hospitalier Universitaire in Nantes, France. In a sequential, randomized, controlled trial, 71.4% of the surgery group compared with 13.3% of the non-surgery group had improved at 12 months.266

Transcutaneous electrical nerve stimulation

Transcutaneous electrical nerve stimulation (TENS) is a well known nonpharmacologic, noninvasive treatment to relieve pain from multiple etiologies. TENS reduces pain through both peripheral and central mechanisms. Centrally, sites in the spinal cord and brainstem that utilize opioid, serotonin, and muscarnic receptors are activated by TENS. In peripheral sites, TENS application produces analgesia though opioid and alpha-2 noradrenergic receptors.267 Weekly intravaginal TENS sessions combined with pelvic floor rehabilitation and biofeedback brought improvement in vulvar pain in 75.8% of all cases.268 In a double-arm randomized placebo-controlled trial there was improvement in all main outcome measures in 40 women with vestibulodynia.269

Subcutaneous stimulation treatment

Peripheral nerve stimulation (PNS) has been successful in the treatment of mononeuropathies. The target site of pain is stimulated transcutaneously, percutaneously or via permanent neuromodultaing implant. Electrodes in the painful area stimulate the affected region and have been helpful for pain conditions such as post-herpetic neuralgia, intractable hip pain, and occipital neuralgia. Clinical success using subcutaneous vulvar stimulation with an 80% improvement in pain has been reported. 270 The mechanism of action is augmented central pain processing in vulvodynia patients as compared to healthy, pain-free controls, based on sensitization of the peripheral and central nervous system.

Radiofrequency (RF) treatment of sacral nerve roots and ganglion impar

An RF lesion will stop nociceptive (A-delta and C fibers) input into the central nervous system without having a destructive effect on motor or sensory (a delta) fibers. Pulsed RF uses relatively high voltage applied near a neural tissue in short pulses, which avoids a significant rise in temperature, and should be more selective for C fiber denervations, so as to decrease the chances for sensory or motor deficit.271 Pulsed radio frequency (PRF) may interfere with normal cell function at the dorsal root ganglion that is induced through changes in myelin and changes in the intracellular axonal components of the pain afferents.272

Use of radio frequency on the ganglion impar has proved effective in visceral pain syndromes and/or sympathetic pain syndromes of the perineal region. Placement of a radio frequency electrode through the sacrococcygeal ligament has been effective in relieving perianal pain when the latter is sympathetically mediated via the ganglion impar.273

Treatment with sacral nerve roots and spinal cord neuromodulation

The FDA supports sacral neuromodulation for disorders of the urinary tract, including idiopathic overactive bladder, urinary incontinence, or chronic nonobstructive urinary retention; pelvic floor disorders have not been approved as an indication for this technique.274 A small study of five women with chronic pelvic pain treated with lumbar and sacral nerve root stimulation was adequate to control paresthesias in all patients and pain scores declined from 9 to 2.275 In another single case, sacral neuromodulation for treatment of vestibulodynia resulted in excellent patient satisfaction after two years of follow up.276 In another isolated case of a 21 year old female with intractable vulvar pain without response to vulvar vestibulectomy with Bartholin gland excision, researchers concluded that spinal cord stimulation may offer a new treatment for women with intractable neuropathic vulvar pain.277

Mindfulness and mindfulness meditation focus on becoming aware of all incoming thoughts and feelings, and accepting them without attaching or reacting to them.278 Mindfulness improves conscious attention and awareness, fosters well being, decreases pain and catastrophizing, and increases positive emotional states. 279 Mindfulness-based cognitive therapy utilizes the traditional cognitive therapy methods with the addition of mindfulness and mindfulness meditation. In a matter of weeks, novice meditators have been shown to develop brain changes associated with memory learning, emotion regulation, self-awareness, cognitive flexibility in support of perspective taking, and less stress. In long term meditators brain scans show even more of these positive effects. 280 With encouragement of women to exercise, help others, engage in enjoyable social interaction or a pleasant activity, play, laugh, learn something useful and practice mindfulness or a meaningful spiritual activity, clinicians will be promoting positive emotions to help decrease pain.

The premise of cognitive behavioral therapy is that changing maladaptive thinking leads to change in affect and in behavior.281 For provoked vulvodynia, the treatment aims to decrease pain, reduce fear of pain, and reestablish satisfying sexual function.282

A 2001 randomized study that looked at CBT, randomized participants to group CBT (CBGT), biofeedback, or vestibulectomy. Women in the three treatment groups reported significant improvement in their pain (47% – 70% for vestibulectomy, 19%-35% for biofeedback, and 21% – 38% for CBGT). While the surgery was significantly more successful than the other two treatments for pain reduction, all three treatments yielded equally significant psychosexual functioning improvements. There was a significantly lower attrition rate for the CBGT group compared with surgery. CBGT participants were more satisfied with their treatment than those in the biofeedback group.283

A 2006 study of CBT for provoked vulvodynia was a prospective evaluation of CBGT efficacy in a large sample. The researchers reported a significant decrease in dyspareunia as well as a significant improvement in sexual satisfaction and perceived pain control.284

A 2005 Cochrane Review confirmed modest positive effects from CBT on pain in various clinical conditions compared to other psychological treatments.285 CBT can increase a woman’s sense of control over her pain. It encourages positive expectations about pain severity that are powerful reducers of pain intensity.286

In a 2015 Swedish study, 60 women suffering from provoked vestibulodynia were treated over a 10-week period with a combination of mucosal desensitization and pelvic floor exercises and CBT. There was a statistically significant increase in sexual fantasies, increased sexual pleasure, excitement, and vaginal lubrication after completion of treatment. Pain occurred less often, resulting in significantly less avoidance of sexual intercourse, increased frequency of self-stimulation and intercourse.287

A 2019 randomized controlled study set out to compare the effectiveness of mindfulness-based group cognitive behavior therapy (M-gCBT) versus education support group therapy for the pain and distress associated with provoked localized vulvodynia. Participants were randomly allocated to either M-gCBT or education support. Average tampon test pain scores decreased compared with baseline at every time point in both study groups. Equally important are the sexual outcomes. Almost all outcome measures improved after the 8-week M-gCBT course with sustained improvement at the 6-month follow-up. When compared with education support, M-gCBT exhibited significantly improved Female Sexual Function Index and Generalized Anxiety Disorder  scores immediately after intervention and these were sustained at 3 and 6 months. The Beck Depression Index in the M-gCBT group showed significantly greater improvement compared with education support at 6 months. Finally, because both groups showed improvement in all sexual outcome domains, it implies that either treatment may be beneficial. 288

CBT has not been studied for generalized vulvodynia but appears to be a promising, readily available modality without negative side effects in need of further study.

Other resources include:

The Benson-Henry Institute for Mind Body Medicine at Massachusetts General Hospital:
Mindfulness-Based Stress Reduction (MBSR) worldwide program directory

Physical therapy to the pelvic floor

Pelvic floor physical therapy and biofeedback are modalities that are used frequently by those who treat women with vulvodynia. These are discussed in (Annotation L The pelvic floor.)

Adjunctive and alternative therapy

There are few studies that have looked at adjunctive or alternative therapies. The ones that have been done so far lack controls and randomization.


A single case study289 and another study of eight women290 showed significant reduction of pain.

Hypoallergenic vulvar hygiene

A prospective evaluation of a hypoallergenic vulvar hygiene program of 14 specific practices targeted for provoked vulvodynia. Twenty percent of the participants had a complete response; 57% had a partial response.291  A limitation was the inability to identify the impact of each of the strategies.


A prospective study of the efficacy of acupuncture showed that participants reported significant improvement in quality of life but their pain response was not reported.292

Surgical intervention

Vestibulectomy (modified perineoplasty) is often recommended for women who have failed medical management of their provoked pain. Patients with spontaneous pain or pain lateral to Hart’s line are not considered appropriate candidates. Preoperative pain mapping in the operating room prior to induction of anesthesia is essential to outline the areas of pain.

The surgery consists of a U-shaped incision in the vestibule starting at the level of Skene’s glands or lower, carried down laterally along Hart’s line medially to the perianal skin and extended superiorly to the level of the mapped pain on the opposite side. The vestibule is dissected medially to include the hymenal remnants, and the specimen is excised. The margins between Hart’s line and the medial paraurethral and vaginal tissue are re-approximated with sutures. Some surgeons mobilize the margin of the vaginal mucosa and bring the tissue inferiorly (vaginal advancement) to suture in place over the excised area from 5-7 o’ clock. Vestibulectomy technique may also utilize the Woodruff and Parmley perineoplasty,293 or a modified vestibulectomy developed by Goetsch, limiting the excision to the posterior fourchette.294

Disparate results have been reported for vestibulectomy.295 Most authors recognize that the absence of randomization leads to bias.296 Reported levels of satisfaction with the surgery span a wide range: 21%297. A retrospective questionnaire was administered to 37 women who had undergone vestibulectomy. Eight women reported being completely pain free after surgery, whereas the remaining 29 women reported various levels of pain and decreased sexual function. the authors concluded that vestibulectomy provides a suboptimal response to surgical treatment. The next value in the range was 40%298;52%299;56%300;66.7%301. These researchers conducted a review and concluded that surgery seems to be effective, although the specific procedure employed is of little importance. When these authors compared long-term well-being after surgery vs. conservative treatment, they found that dyspareunia decreased significantly in both groups; however, some with severe vestibulitis could benefit from vestibulectomy, although results are similar to conservative treatment: visual analogue scale (VAS) reductions of 66.7% in the surgery group and 78.1% in the conservative treatment group. A higher value is reported by Bergeron, et al: 68%.302. These researchers compared vestibulectomy with biofeedback and cognitive behavioral therapy. Surgery yielded pain reduction two times higher (68%) than the behavioral treatments. No behavioral treatment worsened the pain, but in the surgical group, 9% had worsened pain by the time of follow-up: 30378%304 83%305;91%306

The surgical treatment studies have methodological deficiencies. Besides the limitations of no controls or comparison groups in the majority of the studies, only the two cited above are randomized. Other weaknesses include a lack of a double-blind evaluation process, lack of descriptive information about the women in the sample, and no depiction of how pain was measured at baseline. Pain was evaluated subjectively without standardized tools. Follow up time periods vary between studies with no initial definition of successful outcome. Surgical technique varies, although there is currently insufficient evidence to support that any one specific vestibulectomy surgical technique is superior to another.307 Surgery is reported to have a placebo effect of 35%,308 and we know that a 40%-50% placebo effect is documented in randomized controlled trials of nonsurgical interventions for provoked vulvodynia.309 310 311

Despite the methodological weaknesses, surgery has continued to be cited in the literature as a sound treatment option, albeit not a first line intervention.312 The most recent review of the literature indicates that despite a fair amount of evidence, as above, of the effects of vesitibulectomy, such evidence is not enough to accurately determine the degree of effectiveness of these treatments, as studies were performed without placebo control groups.313

A study from 1999 to 2005 of two groups treated with conservative management or posterior vestibulectomy compared longterm well-being of women who needed surgery or did not need surgery in the treatment of severe vulvar vestibulitis syndrome. Longterm sexual well-being did not differ between the two groups. Overall, 89% of the women in both groups were satisfied with the treatment. Women with atopic skin problems were less likely to need surgery (odds ratio 0.2; 95% confidence interval 0.1-0.7).314

A recent descriptive study was to analyze relief of pain, quality of life (QoL), and complications associated with combining surgery with conservative treatments among LPV patients, both in short term and after 3 years of follow-up. The study population consisted of a retrospective patient cohort of surgically (n = 16) and only conservatively (n = 50) treated LPV patients. QoL data were assessed by a validated questionnaire (RAND-36). Data were collected by reviewing patient records and by aid of postal questionnaires. Efficacy of treatments in relief of pain was measured by numerical rating scale (NRS). Two months after surgery, the NRS scores assessed by a physician were lower in the surgery group than in patients treated only conservatively (p = 0.008). However, after a median of 36 months of follow-up, self-reported NRS scores and QoL showed no difference between the two patient cohorts. Complication rate after vestibulectomy was 18.8%. The findings suggest that combining surgery with conservative treatments may result in a more effective short-term reduction of pain. However, the effect seemed to be only temporary, as no long-term benefit was achieved.315


It is important to recognize that with the 2015 classification of pain there are many possible sources of pain to be considered.  We are frequently able to determine a known cause of vulvar pain, especially early desquamative inflammatory vaginitis, that appears to sensitize the vestibule, and the multiple causes of high tone pelvic floor dysfunction. The need to perform vestibulectomy continues to decline for us.



  1. Bohm-Starke N, Ramsay KW, Lytsy P, Nordgren B, Sjöberg I, Moberg K, Flink I. Treatment of Provoked Vulvodynia: A Systematic Review. J Sex Med. 2022 May;19(5):789-808. doi: 10.1016/j.jsxm.2022.02.008. Epub 2022 Mar 21.PMID:35331660
  3. Falsetta M,  et al. Specialized Pro-resolving Mediators Reduce Pro-nociceptive Inflammatory Mediator Production in Models of Localized Provoked Vulvodynia. J Pain. 2021 Oct;22(10):1195-1209. doi: 10.1016/j.jpain.2021.03.144. Epub 2021 Apr 1.
  4. Falsetta M,  et al. Specialized Pro-resolving Mediators Reduce Pro-nociceptive Inflammatory Mediator Production in Models of Localized Provoked Vulvodynia. J Pain. 2021 Oct;22(10):1195-1209. doi: 10.1016/j.jpain.2021.03.144. Epub 2021 Apr 1.
  5.[/efn_note] The new classification “genito-pelvic pain/penetration disorder” in the DSM-55American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5). 5th ed. Washington, DC: APA; 2013
  6. Vieira-Baptista, Pedro MD; Lima-Silva, Joana MD. Is the DSM-V Leading to the Non Diagnosis of Vulvodynia?. Journal of Lower Genital Tract Disease 20(4):p 354-355, October 2016. DOI:10.1097/LGT.0000000000000250
  7. Henzell H, Berzins K, Langford JP. Provoked vestibulodynia: current perspectives. Int J Womens Health. 2017 Sep 11;9:631-642. doi: 10.2147/IJWH.S113416. PMID: 28979166; PMCID: PMC5602415.
  8. Vieira-Baptista, Pedro MD; Lima-Silva, Joana MD. Is the DSM-V Leading to the Non Diagnosis of Vulvodynia?. Journal of Lower Genital Tract Disease 20(4):p 354-355, October 2016. | DOI: 10.1097/LGT.0000000000000250
  9. Bergeron S, Reed BD, Wesselmann U, Bohm-Starke N. Vulvodynia. Nat Rev Dis Primers. 2020 Apr 30;6(1):36. doi: 10.1038/s41572-020-0164-2. PMID: 32355269.
  10. Bergeron S, Reed BD, Wesselmann U, Bohm-Starke N. Vulvodynia. Nat Rev Dis Primers. 2020 Apr 30;6(1):36. doi: 10.1038/s41572-020-0164-2. PMID: 32355269.
  11. Torres-Cueco R, Nohales-Alfonso F. Vulvodynia-It Is Time to Accept a New Understanding from a Neurobiological Perspective. Int J Environ Res Public Health. 2021 Jun 21;18(12):6639. doi: 10.3390/ijerph18126639. PMID: 34205495; PMCID: PMC8296499.
  12. Adapted from the 2015 Consensus Statement which applied these descriptors to vulvodynia alone but which can also be applied to any pain.
  13. Bornstein, Jacob MD, MPA1; Preti, Mario MD2; Simon, James A. MD3, et al. Descriptors of Vulvodynia: A Multi Societal Definition Consensus (International Society for the Study of Vulvovaginal Disease, the International Society for the Study of Women Sexual Health, and the International Pelvic Pain Society). Journal of Lower Genital Tract Disease 23(2):p 161-163, April 2019. | DOI: 10.1097/LGT.0000000000000461
  14. Bornstein J, Maman M, Abramovici H. “Primary” versus “secondary” vulvar vestibulitis: One disease, two variants. Am J Obstet Gynecol. 2001;184:28–31.
  15. Leclair CM, Goetsch MF, Korcheva VB, Anderson R, Peters D, Morgan TK. Differences in primary compared with secondary vestibulodynia by immunohistochemistry. Obstet Gynecol. 2011 Jun;117(6):1307-1313. doi: 10.1097/AOG.0b013e31821c33dc. PMID: 21606740; PMCID: PMC3104470.
  16. adapted from the 2015 Consensus Statement; the original was in alphabetical order.
  17. Merlino L, Titi L, Pugliese F, D’Ovidio G, Senatori R, Rocca CD, Piccioni MG. Vulvodynia: Pain Management Strategies. Pharmaceuticals (Basel). 2022 Dec 5;15(12):1514. doi: 10.3390/ph15121514. PMID: 36558965; PMCID: PMC9781267.
  18. Goldstein AT. Diagnostic and treatment algorithm for women with vulvodynia and sexual pain disorders. In Female Sexual Pain Disorders, Evaluation and Management. Second edition. Goldstein, Pukall, and Goldstein editors. John Wiley and sons, 2021.

    The word “subgroups” must be interpreted within contexts, though, as different specialists (such as neurologists and physical therapists, as well as researchers looking at the physiology of vulvodynia) may use the term uniquely within their own specialty. The factors will be addressed under Pathophysiology below. In some cases, there is overlap of “known” and “unknown” causes and, with future study, more factors will move into the “known” column.

    • Inflammation
    • Immunology
    • Genetics
    • Hormonal influences (e.g. endogenous or exogenous) 
    • Musculoskeletal (e.g. pelvic muscle weakness or overactivity, myofascial, biomechanical)
    • Neurologic mechanisms
    • Central (spine, brain)
    • Peripheral
    • Neuroproliferative
    • Pudendal nerve related
    • Comorbidities and other pain syndromes (e.g. painful bladder syndrome, fibromyalgia, irritable bowel syndrome, temporomandibular disorder) 
    • Psychosocial factors (e.g. stress, mood, interpersonal, coping, role, sexual function) 
    • Structural defects (e.g., perineal descent)

    Localized provoked vulvodynia/vestibulodynia, (pain with light touch in the vestibule, present for at least three months, without identifiable cause, abbreviated here as LPV/PVD because both “LPV” and “PVD” are used in different studies) is the focus of most researchers because it is more common than other types of vulvar pain in premenopausal women,19 Sadownik LA. Etiology, diagnosis, and clinical management of vulvodynia. Int J Womens Health. 2014;6:437–49.

  19. Clare CA, Yeh J. Vulvodynia in adolescence: childhood vulvar pain syndromes. J Pediatr Adolesc Gynecol. 2011;24(3):110–115.
  20. Harlow, B. L. et al. Prevalence of symptoms consistent with a diagnosis of vulvodynia: population based estimates from 2 geographical regions.2014 Am. J. Obstet. Gynecol. 210, 40.e1–8. – DOI
  21. Reed BD, Harlow SD, Sen A, et al. Prevalence and demographic characteristics of vulvodynia in a population-based sample. Am J Obstet Gynecol. 2012;206(2):170.e1–e9.
  22. IASP Task Force on Taxonomy, iasp-pain.orf[
  23. Melzack R. Evolution of the neuromatrix theory of pain. The Prithvi Raj Lecture: presented at the Third World Congress of World Institute of Pain, Barcelona 2004. Pain Practice. 2005;5(2):85-94.
  24. Micheletti L, Radici G, Lynch P. Provoked vestibulodynia: inflammatory, neuropathic or dysfunctional pain? A neurobiological perspective. J Obstet Gynecol.  2014 May;34 (4): 285-8.
  25. Wesselman U, Bonham A, Foster D. Vulvodynia: current state of the biologic science. Pain. 2014 Sep: 155(9): 1696-1701
  26. Bohm-Starke N, Hilliness M, et al. Psychophysical evidence of nociceptor sensitization in vulvar vestibulitis syndrome. Pain.2001; 94(2):177-83.
  27. Woolf CJ, Ma Q (August 2007). “Nociceptors–noxious stimulus detectors.” Neuron 55 (3): 353–64. doi:10.1016/j.neuron.2007.07.016. PMID 17678850.
  28. Besson JM. The neurobiology of pain. Lancet 1999; 353:1610-5.
  29. Marchand S. Applied pain neurophysiology. In: Beaulieu P, Lussier D, Porreca F & Dickenson A. Pharmacology of pain. Seattle: International Association for the Study of Pain Press, 2010, p. 3–26.
  30. Skevington S. Psychology of pain. New York: Wiley; 1995. ISBN 0-471-95771-2. p. 9.
  31. Skevington, S. M. (1995). Psychology of pain. Chichester, UK: Wiley. p. 18. ISBN 0-471-95771-2.
  32. Craig AD. Pain mechanisms: labeled lines versus convergence in central processing. Annu. Rev. Neurosci.. 2003;26:1–30
  33. Campbell JN, Meyer RA. Mechanisms of neuropathic pain. Neuron 2006;52(1):77-92.
  34. Latremoliere A, woolf CJ. Central sensitization: a generator of pain hypersensitivity by central plasticity. J Pain 2009; (10):(9):895-926
  35. Credit: Roberts WJ. A hypothesis in the physiological basis for causalgia and related pain. Pain 1986; 24:297-311.
  36. Neblett R, Cohen H, Choi Y, et al. The central sensitization inventory (CSI):Establishing clinically-significant values for identifying central sensitivity syndromes in an outpatient chronic pain sample. J Pain. 2013 May; 14(5):438-45.
  37. Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, Hansson P, Hughes R, Nurmikko T, Serra J. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology. 2008;70(18):1630–5.
  38. Bridges D, Thompson SWN. Mechanisms of neuropathic pain. Br J Anaesth 2001;87:12-26.
  39. Voscopoulos C, Lerna M. When does acute pain become chronic? Br J Anaesthesia 2010; 305(51):169-185.
  40. Paice JA. Mechanisms and management of neuropathic pain in cancer. J. Support Oncol.. 2003;1(2):107–20. PMID 15352654.
  41. Bridges D, Thompson SWN, Rice ASC. Mechanisms of neuropathic pain. Br J Anaesth 2001; 87:12-26.
  42. Craig AD. A new view of pain as a homeostatic emotion. Trends Neurosci 2003;26(6):303-7.
  43. Craig AD. Interoception: the sense of the physiological condition of the body. Curr Opin Neurobiol. 2002;13(4):500-5.
  44. Amandusson A, Biomavist A. Estrogenic influences in pain processing. Frontiers in Neuoroendocrinology, 2013;34(10):329-49.
  45. Holdcroft A, Berkley KJ. Sex and gender differences in pain and its relief. In: Wall PD, Melzack R, eds. Textbook of pain. New York: Churchill Livingstone; 2005.
  46. Wiesenfeld-Hallin Z. Sex differences in pain perception. Gend Med 2005; 2(3):137-45.
  47. Unruh AM. Gender variations in clinical pain experience. Pain 1996; 65(3):123-67.
  48. Veldhuijzen DS, Keaser ML, Traub DS, et al. The role of circulating sex hormones in menstrual cycle-dependent modulation of pain-related brain activation. Pain 2013;154:548-59.
  49. Greenspan JD, Craft RM, LeResche L et al. Consensus Working Group of the Sex, Gender, and Pain SIG of the IASP, Studying sex and gender differences in pain and analgesia: a consensus report. Pain 2007;132:S26-45.
  50. Kow LM, Pfaff DW. Effects of estrogen treatment on the size of receptive field and response threshold of pudendal nerve in the female rat. Neuroendocrinology 1972; 13(4-5):299-313.
  51. Foster DC, Palmer M, Marks J. Effect of vulvovaginal estrogen on sensorimotor response of the lower genital tract: a randomized controlled trial. Obstet Gynecol 1999; 94:232-7.
  52. Gintzler AR. Endorphin-mediated increases in pain threshold during pregnancy. Science, 1980; 210:193-5.
  53. Hapidou EG, Rollman GB. Menstrual cycle modulation of tender points. Pain, 1998; 77:151-61.
  54. Crofford LJ. Neuroendocrine abnormalities in fibromyalgia and related disorders. AM J Med Sci 1998; 315:359-66.
  55. MacLean AB, Nicol LA , Hodgins MB. Immunohostochenical localization of estrogen receptors in the vulva and vagina. J Repro Med 1990; 35:1015-6.
  56. Buchanan DL, Kurita T, Taylor JA, et al. Role of stromal and epithelial estrogen receptors in vaginal epithelial proliferation, stratification, and cornification. Endocrinology 1998; 139:4345-52.
  57. Giraldi A, Alm P, Werkstrom V, Myllymaki L, Wagner G, Andersson KE. Morphological and functional characterization of a rat vaginal smooth muscle sphincter. Int J Impot Res 2002; 14:271–282.
  58. Hilliges M. Falconer C, Emman-Ordeberg G, Johansson O. Innervation of the human vaginal mucosa as revealed by PGP 9.5 immunohistochemistry. Acta Anat. 1995; 153:119-126.
  59. Munarriz R, Kim SW, Kim NN, Traish A, Goldstein I. A review of the physiology and pharmacology of peripheral (vaginal and clitoral)female genital arousal in the animal model. J Urol 2003; 170(2 Pt 2):S40–S44.
  60. Ting AY, Blacklock AD,Smith PG. Estrogen regulates vaginal sensory and autonomic nerve density in the rat. Bio Reprod 2004; 71:139701404.
  61. Blomqvist A. Sex hormones and pain: a new role for brain aromatase. J Comp Neurol 2000; 423(4):549-51.
  62. Lucas PC, Granner DK. Hormone response domains in gene transcription. Annu Rev Biochem 1992; 61:1131-73.
  63. Amandusson A, Hermanson O, Blomqvist A. Estrogen receptor-like immunoreactivity in the medullary and spinal dorsal horn of the female rat. Neurosci Lett, 1995; 196:25-28.
  64. Giamberardino MA , Berkley KJ, Iezzi S, de Bigontina P, Vecchiet L. Pain threshold variations in somatic wall tissues as a function of menstrual cycle, segmental site and tissue depth in non-dysmenorrheic women, dysmenorrheic women and men. Pain, 1997; 721(2):187-97.
  65. Evrard H, Baillien M, Foidart A, et al. Localization and controls or aromatase in the quail spinal cord. J Comp Neurol 2000; 423:552-64.
  66. Naftolin F, Ryan KJ, Petro Z. Aromatization of androstenedione by the diencephalon. J Clin Endocrinol Metabol 1971; 33:368-70.
  67. Blomqvist A. Sex hormones and pain: a new role for brain aromatase. J Comp Neurol 2000;423(4):549-51.
  68. Lange IG, Hartel A, Meyer HH. Evolution of oestrogen functions in vertebrates. J Steroid Biochem Mol Biol 2002;83(1-5):219-26.
  69. Thornton JW. Evolution of vertebrate steroid receptors from an ancestral estrogen receptor by ligand exploitation and serial genome expansions. Proc Natl Acad Sci USA 2001; 98(10):5671-6.
  70. Stening K, Eriksson O, Wahren L, Berg G, Hammar M, Blomqvist A. Pain sensations to the cold pressor test in normally menstruating women: comparison with men and relation to menstrual phase and sex steroid levels. Am J Physiol Regul Integr Com Physiol 2007; 293(4):R1711-6.
  71. Veldhuijzen DS, Keaser ML, Traub DS, et al. The role of circulating sex hormones in menstrual cycle-dependent modulation of pain-related brain activation. Pain. 2013;154(4):548-9.
  72. Kao A. Binik YM, Amsel R, et al. Biophyscosocial predictors of postmenopausal dyspareunia: the role of steroid hormones, vulvovaginal atrophy, cognitive-emotional factors, and dyadic adjustment. J Sex Med 2012;9:2066-76.
  73. Sherman J, LeReseche L. Does experimental pain response vary across the menstrual cycle? A methodological review. Am J Physiol Regul Integr Comp Physiol 2006;291:R245-56.
  74. Sherman J, LeReseche L. Does experimental pain response vary across the menstrual cycle? A methodological review. Am J Physiol Regul Integr Comp Physiol 2006;291:R245-56.
  75. Amandusson A, Biomavist A. Estrogenic influences in pain processing. Frontiers in Neuoroendocrinology, 2013;34(10):329-49.
  76. Kuba T, We HB, Mazarian A, Festa ED, Barr GA, et al. Estradiol and progesterone differentially regulate formalin-induced nociception in ovariectomized female rats. Horm Beha 2006;49:441-9.
  77. Bouchard C, Brisson J, Fortier M, Morin, Blanchette C. Use of oral contraceptive pills and vulvar vestibulitis: a case control study. Am J Epidemiol 2002; 156(3):254-261.
  78. Eva LJ, MacLeanAB, Reid WM et al. Estrogen receptor expression in vulvar vestibulitis syndrome. Am J Obstet Gynecol 2003; 189:458-61.
  79. Bohm-Starke N, Johannesson U, Hilliges M, Rylander E, Torebjork E. Decreased mechanical pain threshold in the vestibular mucosa of women using oral contraceptives: a contributing factor in vulvar vestibulitis? J Reprod Med 2004; 49(11):888-892.
  80. Greenstein A, Ben-Aroya Z, Fass O, et al. Vulvar vestibulitis syndrome and estrogen dose of oral contraceptive pills. J Sexual Med. 2007; 4(6):1679-1683.
  81. Goldstein AT, Belkin ZR, Krapf JM, et al. Polymorphisms of the androgen receptor gene and hormonal contraceptive induced provoked vestibulodynia. J Sex Med 2014; 11(11):2764-71.
  82. Danielsson I, Sjoberg I, Stenlund H, Wikman M. Prevalence and incidence of prolonged and severe dyspareunia in women; results from a population study. Scand J Public Health 2003; 31(2):113-118.
  83. Harlow B, Vitonis AF, Stewart EG. Influence of oral contraceptive use on the risk of adult-onset vulvodynia. J Repro Med 2008; 53(2):102-110.
  84. Lee M, Morgan M, Rapkin A. Clitoral and vulvar vestibular sensation in women taking 20 mcg ethinyl estradiol combined oral contraceptives: a preliminary study. J Sex Med 2011; 8(1):213-8.
  85. Reed B, Harlow S, Legoki L, Helmuth M, Haefner H, Gillespie B, Sen A. Oral contraceptive use and risk of vulvodynia: a population-based longitudinal study. BJOG. 2013 Dec;120(13):1678-84.
  86. Baker PK. Musculoskeletal origins of chronic pelvic pain. Obstet Gynecol Clin North America. 1993; 20(4):719-42.
  87. Fitzpatrick C, DeLancey O, Elkins T. Vulvar vestibulitis and interstitial cystitis: a disorder of urogenital sinus-derived epithelium. Obstet Gynecol. 1993; 81:860-62.
  88. Arnold LD, Bachmann GA, Rosen R, Kelly S, Rhoads GG. Vulvodynia: characteristics and associations with comorbidities and quality of life. Obstet Gynecol. 2006;107:617-24
  89. Bullones Rodriguez MA, Buchwald DS. National Institute of diabetes and Digestive and Kidney Diseases Working Group on Urological Pelvic Pain. Evidence for overlap between urological and non urological unexplained clinical conditions. J Urol. 2013;189(Suppl):S66-74
  90. Reed BD, Harlow SD, Sen A, Edwards RM, Chen D, Haefner HK. Relationship between vulvodynia and chronic co-morbid pain conditions. Obstet Gynecol. 2012;120:145-51.
  91. Lester R, Brotto L, Sadownik L. Provoked vestibulodynia and the health care implications of co-morbid pain conditions. J Obstet Gynaecol Can. 2015 Nov; 37(11)995-2005.
  92. Lester R, Brotto L, Sadownik L. Provoked vestibulodynia and the health care implications of co-morbid pain conditions. J Obstet Gynaecol Can. 2015 Nov; 37(11)995-2005.
  93. Moyal-Barracco M, Lynch PJ. 2003 ISSVD terminology and classification of vulvodynia: a historical perspective. J Reprod Med. 2004;49:772-777.
  94. Wesselman U, Bonham A, Foster D. Vulvodynia: Current state of the biologic science. Pain. 2014 Sep: 155(9): 1696-1701.
  95. Sadownik LA. Etiology, diagnosis, and clinical management of vulvodynia. Int J Womens Health. 2014;6:437-49
  96. al-Safi ZA, Santoro N. Menopausal hormone therapy and menopausal symptoms. Fertility and Sterility. 2014 Apr; 101(4):905–15
  97. al-Safi ZA, Santoro N. Menopausal hormone therapy and menopausal symptoms. Fertility and Sterility. 2014 Apr; 101(4):905-15
  98. Turner MLC, Marinoff SC. Pudendal neuralgia. Am J Obstet Gynecol. 1991; 165:1233-1236.
  99. Ramsden CE, McDaniel MC, Harmon RL, Renney KM, Faure A. Pudendal nerve entrapment as source of intractable perineal pain. Am J Phys Med Rehabil. 2003;82(6):479-484.
  100. Robert R, Prat-Pradal D, Labat JJ, et al. Anatomic basis of chronic perineal pain:role of the pudendal nerve. Surg Radiol Anat. 1998; 20:93-98.
  101. Silbert PL, Dunne JW, Edis RH, et al. Bicycling induced pudendal nerve pressure neuropathy. Clin Exp Neurol. 1991; 28:191-240.
  102. Layzer RB, Connant Ma. Neuralgia in recurrent herpes simplex. Arch Neurol. 1974; 31:233-237.
  103. Masata J, Hubka P, Martan A. Pudendal neuralgia following transobturator inside-out tape procedure (TVT-O)–case report and anatomical study. Int Urogynecol J. 2012 Apr; 23(4):505-507
  104. Marcus-Braun N, Bourret A, von Theobald P. Persistent pelvic pain following transvaginal mesh surgery: a cause for mesh removal. Eur J Obstet Gynecol Reprod Biol. 2012 Mar 29. [Epub ahead of print]
  105. Amarenco G, Ismael SS, Bayle B, et al. Electrophysiological analysis of pudendal neuropathy following traction. Muscle Nerve 2001;24:116–119.
  106. Harlow B, Wise L, Stewart E. Prevalence and predictors of chronic lower genital tract discomfort. Am J Obstet Gynecol 2001; 185:545-50.
  107. Smith E, Ritchie J, Galask R, et al. Case-control study of vulvar vestibulitis risk associated with genital infections. Infec Dis Obstet Gynecol 2002;10:193-202.
  108. Farmer M, Taylor A, Bailey A, et al. Repeated vulvovaginal fungal infections cause persistent pain in a mouse model of vulvodynia. Sci Transl Med 2011; 2:101ra91.
  109. Rylander E, Berglund A, Krassny C, Petrini B. Vulvovaginal candida in a young sexually active population: prevalence and association with oro-genital sex and frequent pain at intercourse. Sex Transm Infect. 2004;80:54-57.
  110. Pyka R, Wilkinson E, Friedrich EG Jr, Croker B. The histopathology of vulvar vestubulitis syndrome. Int J Gynecol Pathol 1988;7:249-57.
  111. Goetsch M, Morgan T, Korcheva V, Li H, et al. Histologic and receptor analysis of primary and secondary vestibulodynia and controls: a prospective study. Am J Obstet Gynecol 2010; 202:614.e1-8.
  112. Bohm-Starke N, Falconer C, Rylander E, Hilliges M. The expression of cyclooxygenase 2 and inducible nitric oxide synthetase indicates no active inflammation in vulvar vestibulitis. Acta Obstet Gynecol Scand 2001; 80:638-44.
  113. Eva L, Rolfe K, MacLean A, et al. Is localized, provoked vulvodynia an inflammatory condition? J Reprod Med 2007; 52:379-84.
  114. Foster D, Hasaday J. Elevated tissue levels of interleukin-1 beta and tumor necrosis alpha factor in vulvar vestibulitis. Obstet Gynecol 1997;89:291-6.
  115. Foster D, Piekarz K, Murant T, et al. Enhanced synthesis of proinflammatory cytokines by vulvar vestibular fibroblasts: implications for vulvar vestibulitis. Am J Obstet Gynecol 2007; 196:346.e1-8
  116. Gerber S, Bongiovanni A, Ledger W, Witkin S. Defective regulation of the pro-inflammatory immune response in women with vulvar vestibulitis syndrome. Am J Obstet Gynecol 2002;186:696-700.
  117. Gerber S, Bogiovanni A, Ledger W, Witkin S. A deficiency in interferon-alpha production in women with vulvar vestibulitis. Am J Obstet Gynecol 2002; 186:361-4.
  118. Tympanidis P, Terenghi G, and Dowd P: Increased innervation of the vulval vestibule in patients with vulvodynia. Br J Dermatol 2003; 148: pp. 1021-1027.
  119. Bornstein J., Goldschmid N., and Sabo E.: Hyperinnervation and mast cell activation may be used as histopathologic diagnostic criteria for vulvar vestibulitis. Gynecol Obstet Invest 2004; 58: pp. 171-178.
  120. Halperin R, Zehavi S, Vaknin Z, Ben-Ami I., Pansky M, and Schneider D: The major histopathologic characteristics in the vulvar vestibulitis syndrome. Gynecol Obstet Invest 2005; 59: pp. 75-79
  121. Papoutis D, Haefner HK, Crum CP, et al. Vestibular mast cell density in vulvodynia: a case controlled study. J Low Genit Dis 2016. May 24 (epubahead of print)
  122. Tommola P, Butzow R, Unkila-Kalio L, Paavonen J, Meri S. Activation of vestibule-associated lymphoid tissue in localized provoked vulvodynia. Am J Obstet Gynecol 2015;212(4):476e1-8
  123. Tommola P, Butzow R, Unkila-Kalio L, Paavonen J, Meri S. Activation of vestibule-associated lymphoid tissue in localized provoked vulvodynia. Am J Obstet Gynecol 2015;212(4):476e1-8
  124. Brandtzaeg P, Kiyono H, Pabst R, and Russell M.W: Terminology: nomenclature of mucosa-associated lymphoid tissue. Mucosal Immunol 2008; 1: pp. 31-37.
  125. Brandtzaeg P, Kiyono H, Pabst R, Russell M. Terminology: nomenclature of mucosa-associated lymphoid tissue. Mucosal Immunol 2008;1:31-7.
  126. Tommola P, Butzow R, Unkila-Kalio L, Paavonen J, Meri S. Activation of vestibule-associated lymphoid tissue in localized provoked vulvodynia. Am J Obstet Gynecol 2015;212(4):476e1-8
  127. Foster D, Falsetto M, Woeller C, et al. Site-specific mesenchyme control of inflammatory pain to yeast challenge in vulvodynia afflicted and pain-free women. Presented at theXXIII World Congress of the International society for the Study of Vulvovaginal Disease. July 27-29, 2015. New York University, New York City, NY.
  128. Tommola P, Unkila-Kallio L, Paetau A, et al. Immune activation enhances epithelial nerve growth in localized provoked vulvodynia. Presented at the XXIII World Congress of the International society for the Study of Vulvovaginal Disease. July 27-29, 2015. New York University, New York City, NY.
  129. Gunter J. Vulvodynia: new thoughts on a devastating condition. Obstet Gynecol Survey. 2007; 62(12):812-819.
  130. Ru-Jong Ji, Kohno T, Moore K, et al. Central sensitization and LTP: do pain and memory share similar mechanisms? Trends Neurosci 2003; 26:696-705.
  131. Arnold J, Bachmann G, Rosen R. et al. Vulvodynia: characteristics, and associations with co-morbidities and quality of life. Obstet Gynecol 2006; 107:617-624.
  132. Reed BD, Harlow SD, Sen A, Edwards RM, Chen D, Haefner HK. Relationship between vulvodynia and chronic comorbid pain conditions. Obstetrics Gynecol. 2012; 120:145-51
  133. Bullones Rodriguez MA, Afari N, Buchwwald DS. National Institute of Diabetes and Digestive and Kidney Diseases. Working group on Urological Chronic Pelvic Pain. Evidence for overlap between urological and non urological unexplained clinical conditions. J Urol. 2013; 189(Suppl 1):S66-74
  134. Jantos M. Vulvodynia: A psychophysiological profile based on electromyographic assessment. Appl Psychophysiol Biofeedback 2008; 33:29-38.
  135. McEwen B, Seeman T. Allostatic load and allostasis: Summary of the allostatic load working group. 2009: retrieved February 3, 2014 from
  136. McEwen BS, Stellar E. Stress and the individual: Mechanisms leading to disease. Arch Int Med 1993; 153:2093-2101
  137. Rodrigues SM, LeDouxJE, Sapolsky RM. The influences of stress hormones on fear circuitry. Ann Rev Neuroscience 2009; 32:289-313
  138. Ganzel BL, Morris PA, Wethingon E. Allostasis and the human brain: Integrating models of stress from the social and life sciences. Psychological Review 2010; 117(1):134-174
  139. Plante A, Kamm M A. Life events in patients with vulvodynia. BJOG:An International J of Obstet Gynaecol 2008; 115(4):509-14
  140. Harlow BL, Stewart EG. Adult-onset vulvodynia in relation to childhood violence victimization. Am J Epidemiol 2004; 161(9):871-80
  141. Schweinhardt P, Kuchinad A, Pukall CF, Bushnell MC. Increased gray matter density in young women with chronic vulvar pain. Pain 2008; 140(3):411-19
  142. Van Ryckeghem DM, Crombez G, Goubert L, Houwer JD, Onraedt T, Van Damme S. The predictive value of attentional bias towards pain-related information in chronic pain patients: A diary study. Pain 2013; 154:468-75
  143. Arnsten AF. Stress signaling pathways that impair prefrontal cortex structure and function. Nature Reviews Neuroscience 2009;10(6):410-22
  144. Kao A, Binik YM, Amsel R. Funaor D, Leroux N, Khalife S. Biopsychosocial predictors of postmenopausal dyspareunia: The role of steroid hormones, vulvovaginal atrophy, cognitivie-emotional factors and dyadic adjustment. J Sex Med 2012;9:2066-76
  145. Arnold L, Bachmann G, et al. Vulvodynia: Characteristics and associations with comorbidities and quality of life. Obstet Gynecol 2006; 107:617-24
  146. Khandker M, Brady S, Vitonis A, MacLehose R, Stewart EG, Harlow BL. The influence of depression and anxiety on risk of adult onset vulvodynia. J Womens Health 2011; 20:1445-51
  147. Tracy I, Bushnell MC. How neuroimaging studies have challenged us to rethink: Is chronic pain a disease? J Pain 2009; 10:1113-20
  148. Sugama S. Fujita M, et al. Stress induced morphological microglial activation in the rodent brain: Involvement of interleukin-18. Neuroscience 2007; 14:225-8
  149. Tracy I, Bushnell MC. How neuroimaging studies have challenged us to rethink: Is chronic pain a disease? J Pain 2009; 10:1113-20
  150. Basson R. The recurrent pain and sexual sequelae of provoked vestibulodynia: a perpetuating cycle. J Sex Med 2012;9:2077-92
  151. Feder A, Nestler EJ, Charney DS. Nature Reviews Neuroscience 2009; 10(6):446-57
  152. Cohn MA, Fredrickson BL. In search of durable positive psychology interventions: Predictors and consequences of long-term positive behavior change. J Postivie Psychology 2010; 5(5):355-66
  153. Basson R. The recurrent pain and sexual sequelae of provoked vestibulodynia: a perpetuating cycle. J Sex Med 2012;9:2077-92
  154. Solomons CC, Melmed MH, Heitler SM. Calcium citrate for vulvar vestibulitis. A case report. J Reprod Med. 1991 Dec;36(12):879-82.
  155. Baggish MS, Sze EH, Johnson R. Urinary oxalate excretion and its role in vulvar pain syndrome. Am J Obstet Gynecol. 1997 Sep;177(3):507-11.
  156. Harlow BL, Abenhaim HA, Vitonis AF, Harnack L. Influence of dietary oxalates on the risk of adult-onset vulvodynia. J Reprod Med. 2008 Mar; 53(3):171-178.
  157. Greenstein A, Militscher I, Chen J, Matzkin H, Lessing JB, Abramov L.Hyperoxaluria in women with vulvar vestibulitis syndrome. J Reprod Med. 2006 Jun; 51(6):500-502.
  158. Dell JR, Parsons CL. Multimodal therapy for interstitial cystitis. J Reprod Med. 2004; 49:243.
  159. Morin C, Bouchard C, Brisson J, et al. Human papillomaviruses and vulvar vestibulitis. Obstet Gynecol. 2000;95:683-687
  160. Yosipovitch G, Greaves< MW, Schmetz M. Itch. Lancet. 2003; 361:690-694.
  161. Schmelz M, Schmidt R, Bickel A, Handwerker HO, Torebjork HE. Specific C-receptors for itch in human skin. J Neurosci. 1997; 17:8003-8008.
  162. Andrew D, Craig AD. spinothalamic lamina I neurons selectively sensitive to histamine: a central neural pathway for itch. Nat Neurosci. 2001; 4:72-77.
  163. Twycross R, Greaves MW, Handwerker H, et al. Itch: scratching more than the surface. QJM. 2003; 96:7-26.
  164. Pfab F, Valet M, Sprenger T, et al. Temperature modulated histamine-itchin lesional and nonlesional skin in atopic eczema- a combined psycholphysical and neuroimaging study. Allergy 2010; 65:84-94.
  165. Yosipovitch G, Ishiuji Y, Patael RS, et al. The brain processing of scratching. J Invest Dermatol. 2008; 128:10806-11811.
  166. Paus R, Schmeiz M, Biro T, Steinhoff M. Frontiers in pruritus research: scratching the brain for more effective itch therapy. J Clin Investigation. 2006; 116(5):1174-1185.
  167. Ikoma A, Steinhoff M, Stander S, et al. The neurobiology of itch. Nat Rev Neurosci. 2006;7:535-547.
  168. Ventolini G, Barhan S. Vulvodynia. Dermatology Online J. 2008;14(1):1-6.
  169. Phillips N, Brown C, Foster D, et al. Presenting symptoms among premenopausal and postmenopausal women with vulvodynia: a case series. Menopause 2015 Aug 31. [Epub ahead of print]
  170. Stav K, Dwyer PL, Roberts F, Roberts L. Pudendal neuralgia fact or fiction? Obstet Gynecol Survey. 2009; 64(3):190-199.
  171. Stav K, Dwyer PL, Roberts F, Roberts L. Pudendal neuralgia fact or fiction? Obstet Gynecol Survey. 2009; 64(3):190-199.
  172. Labat JJ, Riant T, Robert R, et al. Diagnostic criteria for pudendal neuralgia by pudendal nerve entrapment (Nantes criteria). Neurourol Urodyn. 2008;27:306–310.
  173. Shafik A. Pudendal canal syndrome as a cause of vulvodynia and its treatment by pudendal nerve decompression. Eur J Obstet Gynecol Reprod Biol. 1998;80:215–220.
  174. Popeney C, Ansell V, Renney K. Pudendal entrapment as an etiology of chronic perineal pain: diagnosis and treatment. Neurourol Urodyn. 2007;26:820–827.
  175. Labat JJ, Riant T, Robert R, et al. Diagnostic criteria for pudendal neuralgia by pudendal nerve entrapment (Nantes criteria). Neurourol Urodyn. 2008;27:306–310.
  176. Benson JT, Griffis K. Pudendal neuralgia, a severe pain syndrome. Am J Obstet Gynecol. 2005;192:1663–1668.
  177. Friedrich EG Jr. Vulvar vestibulitis syndrome. J Reprod Med 1987;32(2):110-4.
  178. Labat JJ, Riant T, Robert R, et al. Diagnostic criteria for pudendal neuralgia by pudendal nerve entrapment (Nantes criteria). Neurourol Urodyn. 2008;27: 306–310.
  179. Stav K, Dwyer PL, Roberts F, Roberts L. Pudendal neuralgia fact or fiction? Obstet Gynecol Survey. 2009; 64(3):190-199.
  180. Labat JJ, Riant T, Robert R, et al. Diagnostic criteria for pudendal neuralgia by pudendal nerve entrapment (Nantes criteria). Neurourol Urodyn. 2008;27: 306–310.
  181. Swash M, Snooks SJ. Motor nerve conduction studies of the pelvic floor innervation. In: Henry MM, Swash M, eds. Coloproctology and the Pelvic Floor. 2nd ed. London: Butterworth- Heinemann, 1992:196–206.
  182. Howard EJ. Postherpetic pudendal neuralgia. JAMA. 1985;253(15):2196.
  183. Sadownik LA, Long PJ, Smith KB. Systematic review of treatment outcome measures for vulvodynia. J Low Genit Tract Dis. 2018 Jul;22(3): 251-9
  184. Falsetta ML, Foster DC, Bonham AD, Phipps RP. A review of the available clinical therapies for vulvodynia management and new data implicating pro-inflammatory mediators in pain elicitation. BJOG. 2017 Jan; 124(2): 210-18. doi:10.1111/1471-0528.14157
  185. Bohm-Starke N. Medical and physical predictors of localized provoked vulvodynia. Acta Obstet Gynecol Scand. 2010 Dec;89(12):1504-1510.
  186. Lonky NM, Edwards L, Gunter J, Haefner HK. Vulvar pain syndromes. OBG Management. 2011; 23(10):29-41.
  187. Harlow BL, Stewart EG. A population-based assessment of chronic unexplained vulvar pain: have we underestimated the prevalence of vulvodynia? J Am Med Womens Assoc. 2003;58(2):82-88.
  188. Andrews JC. Vulvodynia interventions- systematic review and evidence grading. Obstet Gynecol Survey 2011:66(5):299-315.
  189. Mandal D, Nunns D, Byrne M, McLelland J, Rani R, Cullimore J, et al. Guidelines for the management of vulvodynia. Br J Dermatol. 2010 Mar 16.
  190. Danby CS, Margesson LJ. Approach to the diagnosis and treatment of vulvar pain. Dermatol Ther. 2010 Sep;23(5):485-504.
  191. Haefner H, Collins M, Davis G, Edwards L, Foster D, Hartmann K, et al. The vulvodynia guideline. J Lower Genit Tract Dis. 2005;9:40-51.
  192. Zolnoun DA, Hartmann KE, Steege JF. Overnight 5% lidocaine ointment for treatment of vulvar vestibulitis. Obstet Gynecol. 2003; 102(1):84-87,
  193. Danielsson I, Torstensson T, Brodda-Jansen G, Boehm-Starke N. EMG biofeedback versus topical lidocaine gel: a randomized study for the treatment of women with vulvar vestibulitis. Acta Obstet Gynecol Scand. 2006;85:1360-7.
  194. Foster DC, Kotok MB, Huang LS, Watts A, Oakes D, et al. Oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trial. Obstet Gynecol. 2010; 116(3):583-593.
  195. Rosen N, Dawson S, Brooks M, Kellogg-Spadt S. Treatment of vulvodynia: Pharmacological and non-pharmacological approaches. Drugs. 201979:483-93.
  196. Rufina K, Kelly KL, Olson M, Nickel JC. Early experience with topical meloxicam and lidocaine combination for the treatment of vulvodynia. Can Urol Assoc J. 2018 Aug; 12(8):252-55
  197. Al-Safi Z, Santoro N. Menopausal hormone therapy and menopausal symptoms. fertility Steril 2014; 101:905-15.
  198. KeppelH, Kopsky D, Saben N.Vulvodynia and proctodynia treated with topical baclofen 5% and palmitoylethanolamide. Arch Gynecol Obstet 2014;290:389-93.
  199. Murina F, Radici G, Bianco V. Capsaicin and the treatment of vulvar vestibulitis syndrome: a valuable alternative? Med Gen Med 2004;6:48,
  200. Steinberg A Oyama I, Rejba A, Kellogg-Spadt S, Whitmore K. Capsaicin for the treatment of vulvar vestibulitis. Am J Obsete Gynecol 2005; 192:1549-53.
  201. Pagano oR, Wong S. Use of amitriptyline cream in the management of entry dyspareunia due to provoked vestibulodynia. J Low Tract dis 2012; 16:394-7,
  202. Boardman Lm Cooper A, Blais L, Rakker C. Topical gabapentin in the treatment of localized and generalized vulvodynia. Obstet Gynecol 2008; 112:579-85.
  203. Bond K, Weerakoon P, Shuttleworth R. A literature review on vulvodynia and distress. Sex Relatsh Ther 2012;27:46-62.
  204. Bergeron S, Likes W, Steben M. Psychosexual aspects of vulvovaginal pain. Best Practice Res Clin Obstet Gynaecol 2014;28:991-9
  205. Dworkin R, Backonja M, Allen R, Argoff C, Bennett G, et al. Advances in neuropathic pain: diagnosis, mechanism, and treatment recommendations Arch Neurol 2003;606:1524-34.
  206. Lonky NM, Edwards L, Gunter J, Haefner HK. Vulvar pain syndromes. OBG Management. 2011; 23(10):29-41.
  207. Dharmshaktu P, Tayal V, Kalra BS. Efficacy of antidepressants as analgesics: a review. J Clin Pharmacol. 2012 Jan;52(1):6-17.
  208. Brown CS, Wan J, Bachman G, Rosen R. Self-management, amitriptyline, and amitriptyline plus triamcinolone in the management of vulvodynia. J Women Health (Larchmt). 2009; 18(2):163-169.
  209. Reed BD, Caron AM, Gorenflo DW, Haefner HK. Treatment of vulvodynia with tricyclic antidepressants: efficacy and associated factors. J Low Genit Tract Dis. 2006; 10(4):245-251.
  210. Eppsteiner E, Boardman L. Stockdale C. Vulvodynia. Best Practice Res Clin Obstet Gynaecol 2014;28: 100-12.
  211. Magnus L. Nonepileptic uses of gabapentin. Epilepsia. 1999;40 Suppl 6:S66-72; discussion S3-4.
  212. Ben-David B, Friedman, M. Gabapentin therapy for vulvodynia. Anesth Anal. 1999;89:1459-1462.
  213. Harris G, Horowitz B, Borgida A. Evaluation of gabapentin in the treatment of generalized vulvodynia, spontaneous. J Reprod Med. 2007; 52:103.
  214. Andrews JC. Vulvodynia interventions- systematic review and evidence grading. Obstet Gynecol Survey. 2011:66(5):299-315.
  215. Brown C, Bachmann G, et al. Gabapentin for the treatment of vulvodynia: a randomized controlled trial.Obstet Gynecol 131;(6):1000-1007.
  216. van Weekhuizen J, Oost J, van der Mejiden W. Generalized unprovoked vulvodynia: A retrospective study of the efficacy of treatment with amitriptyline, gabapentin, or pregabalin. Our J Obstet Gynecol Reprod Biol. 2018;220:118-21,
  217. Melizer-Brody S, Zolnoun D, Steege J, Rinaldi K, Leserman J. Open-label trial of lamotrigine focusing on efficacy in vulvodynia. J Reprod Med. 2009;54:171-8
  218. Pagano R. Vulvar vestibulitis syndrome: an often unrecognized cause of dyspareunia. Just NN Z J Obstet Gneaecol. 1999;39:79-83.
  219. Bornstein J, Livnat G, Stolar Z, et al. Pure versus complicated vulvar vestibulitis: a randomized trial of fluconazole treatment. Gynecol Obstet Invest .2000; 50:194-197.
  220. Rogalski MJ, Kellog-Spadt S, Hoffman AR, et al. Retrospective chart review of vaginal diazepam suppository use in high-tone pelvic floor dysfunction. Int Urogynecol J. 2010; 21:895-899.
  221. Bohm-Starke N, Falconer C, Rylander E, Hilliges M. The expression of cyclooxygenase 2 and inducible nitric oxide synthase indicates no active inflammation in vulvar vestibulitis. Acta Obstet gynecol Scand. 2001; 80:638-644.
  222. Foster D, Hasday J.Elevated tissue levels in interleukin 1-beta and tumor necrosis factor-alpha in vulvar vestibulitis. Obstet Gynecol. 1997;89:291-6.
  223. Brown C, Wan J, Bachmann G, Rosen R. Self management, amitriptyline, and amitriptyline plus triamcinolone in the management of vulvodynia. J Women Health 2009;18:163-9.
  224. Munday P. Treatment of vulval vestibulitis with a potent topical steroid. Sex Transm Infect. 2004;80:154-5.
  225. Dede M, Yemen M, Yilmaz A, Baser M. Successful treatment of persistent vulvodynia with submucous infiltrations of betamethasone and lidocaine. Eur J Obst Gynecol Reprod Biol.2006;124:258-9.
  226. Segal D, Tifheret H, Lazer S. Submucuous infiltration of betamethasone and lidocaine in the treatment of vulvar vestibulitis. Eur J Obst Gynecol Reprod Biol. 2003;107:105-6.
  227. Bergeron S, Khalife S. Dupuis M, McDuff P. A randomized clinical trial comparing group cognitive behavioral therapy and a optical steroid for women with dyspareunia. J Consult Clin Psychol. 2016;84:259-68.
  228. Hermanns K, Junker U, Nolte T. Prolonged-release oxycodone/naloxone in the treatment of neuropathic pain – results from a large observational study. Expert Opin Pharmacother. 2012 Feb;13(3):299-311.
  229. Bajwa ZH, Smith HS. Overview of the treatment of chronic pain. In: UpToDate, Basow DS (Ed), UpToDate, Waltham MA, 2012.
  230. Duhmke RM, Cornblath DD, Hollingshead JR. Tramadol for neuropathic pain. Cochrane Database Syst Rev. 2004; CD003726
  231. Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E. Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. CMAJ 2006; 174:1589
  232. HumanMedicalProducts/ucm213264 (Accessed on July 16, 2008).
  233. Another once-daily formulation of tramadol (Ryzolt). Med Lett Drugs Ther. 2010; 52:39
  234. Boo B, Kamath R, Arriagna-Gomez E, Landry J, Emmaneul E, Joo S, et al. Tetrahydrocannabinol reduces hapten-driven mast cell accumulation and persistent tactile sensitivity in mouse model of allergen-provoked localized vulvodynia. Int J Mol Sci 2019 May 1;20(9). pil: E2163. doin: 10.3390/ljms20092163.
  235. Preti M, Viera-Baptista P, Alessandro Digesu G, Bretschneider CE, et al. The clinical role of LASER for vulvar and vaginal treatments in gynecology and female urology: an ICS/ISSVD best practice consensus document. J Low Genit Tract Dis 2019;23: 151-60
  236. LeClair CM, Goetsch MF,Lee KK, et al. KTP-nd:YAG laser therapy for the treatment of vestibulodynia: a follow-up study. J Reprod Med 2007; 52:53-8
  237. Murina F, Karram M, Salvatore S, et al. Fractional CO2 laser treatment of the vestibule for patients with vestibulodynia and genitourinary syndrome of menopause: a pilot study. J Sex Med 2016;13:1915-7
  238. Lev-Sagie A, Kopitman A, Brzezinski A. Low-level laser therapy for the treatment of provoked vestibulodynia-a randomized, placebo-controlled pilot trial. J Sex Med 2017;14:1403-11
  239. Preti M, Viera-Baptista P, Alessandro Digesu G, Bretschneider CE, et al.The clinical role of LASER for vulvar and vaginal treatments in gynecology and female urology: an ICS/ISSVD best practice consensus document. J Low Genit Tract Dis 2019;23: 151-60
  240. Park J, Chung ME. Botulinum toxin for central neuropathic pain. Toxins (Basel). 2018;10:224. toxins10060224
  241. Matak I, Lackovic Z. Botulinum toxin A, brain and pain. Prog Neurobiol. 2014;119-120:39–59
  242. Andrews JC. Vulvodynia interventions- systematic review and evidence grading. Obstet Gynecol Survey 2011:66(5):299-315
  243. Gunter J, Brewer A, Tawfik O. Botulinum toxin A for vulvodynia: a case report. J Pain. 2004; 5:238-240
  244. Yoon H, Chung WS, Shim BS. botulinu toxin A for the management of vulvodynia. Intl J Impotence Res. 2007; 19:84-87
  245. Abbott JA, Jarvis SK, Lyons SD, Thomson A, Vancaille TG, Botulinum toxin type A for chronic pain and pelvic floor spasm in women. Obstet Gynecol 2006;108:915-923
  246. Adelowo A, Hacker M, Shapiro A, Modest A, ElKadry E. Botulinum toxin type A (Botox) for refractory myofascial pelvic pain. Female Pelvic Med Reconstr Surg 2013; 19(5):288-92.
  247. Karp BI, Tandon H, Vigil D, Stratton P. Methodological approaches to botulinum toxin for the treatment of chronic pelvic pain, vaginismus, and vulvar pain disorders. Int Urogynecol J 2019 Jul;30(7):1071-1081
  248. Karp BI, Tandon H, Vigil D, Stratton P. Methodological approaches to botulinum toxin for the treatment of chronic pelvic pain, vaginismus, and vulvar pain disorders. Int Urogynecol J 2019 Jul;30(7):1071-1081
  249. Karp BI, Tandon H, Vigil D, Stratton P. Methodological approaches to botulinum toxin for the treatment of chronic pelvic pain, vaginismus, and vulvar pain disorders. Int Urogynecol J 2019 Jul;30(7):1071-1081
  250. Murina F, Tassan P, Roberti P. et al. Treatment of vulvar vestibulitis with submucous infiltrations of methylprednisolone and lidocaine: An alternative approach. J Reprod Med 2001; 46(8):713-716
  251. Segal D, Tifneret H, Lazer S. Submucous infiltration of betamethasone and lidocaine in the treatment of vulvar vestibulitis. Eur J Obstet Gynecol Reprod Biol. 2003; 107:105-106
  252. Bergeron S, Khalifé S, Dupuis MJ, McDu P. A randomized clinical trial comparing group cognitive-behavioral therapy and a topical steroid for women with dyspareunia. J Consult Clin Psychol. 2016;84:259–68
  253. Goldstein A, Pukall CF, Brown C, Bergeron S, Stein A, Kellogg-Spadt S. Vulvodynia: assessment and treatment. J Sex Med. 2016;13:572–90
  254. Bornstein J, Pascal B, Abramovici H. Treatment of a patient with vulvar vestibulitis by intramuscular interferon beta: a case report. Eur J Obstet Gynecol Repro Bio. 1991; 42:23709.
  255. Bornstein J. Pascale B, Abramovici H. Intramuscular beta-interferon treatment for severe vulvar vestibulitis. J Reprod Med. 1993; 38:117-120
  256. Rosen NO, Dawson SJ, Brooks M, Kellogg-Spadt S. Treatment of vulvodynia: pharmacological and non-pharmacological approaches. Drugs. 2019 Apr; 79(5):483-93. doing: 10.1007/s40265-019-01085-1
  257. Rapkin AJ, McDonald JS, Morgan M. Multilevel local anesthetic nerve blockade for the treatment of vulvar vestibulitis syndrome. Am J Obstet Gynecol. 2008; 198:41.e1.
  258. Lonky NM, Edwards L, Gunter J, Haefner HK. Vulvar pain syndromes. OBG Management. 2011; 23(10):29-41.
  259. McDonald JS, Spigos DG. Computed tomography–guided pudendal block for treatment of pelvic pain due to pudendal neuropathy. Obstet Gynecol. 2000;95:306–309
  260. Filler A. Diagnosis and management of pudendal nerve entrapment syndromes: impact of MR neurography and open MR-guided injections. Neurosurg Q. 2008;18: 1–6
  261. Fanucci E, Manenti G, Ursone A, et al. Role of interventional radiology in pudendal neuralgia: a description of techniques and review of the literature. Radiol Med. 2009;114(3):425-36
  262. Robert R, Labat J, Bensignor M, et al. Decompression and transposition of the pudendal nerve in pudendal neuralgia: a randomized controlled trial and long term evaluation. Eur Urol. 2005;47(3):403-408
  263. Hibner M, Castellanos M, et al. Pudendal neuralgia. Glob libr women’s med, (ISSN:1756-2228) 2011; DOI 10 3843/GLOWM.10468
  264. Robert R, Labat JJ, Bensignor M, Pascal G, Deschamp C, Raoul S, Olivier H. Decompression and transposition of the pudendal nerve in pudendal neuralgia: a randomized controlled trial and long-term evaluation. European Urology. 2004;47(3):403-408
  265. De Andres J, Sanchis-Lopez N, Asensio-Samper J, et al. Vulvodynia–an evidence based literature review and proposed treatment algorithm. Pain Practice 2015 Jan 12. doi:10. 1111/papr. 12274. [e-pub ahead of print]
  266. Dionisi B, Anglana F, Inghirami P, et al. Use of transcutaneous electrical stimulation and biofeedback for the treatment of vulvodynia (vulvar vestibular syndrome): result of 3 years of experience. Minerva Ginecol 2008; 60:485-91.
  267. Murina F, Bianco V Radici G, et al. Transcutaneous electrical nerve stimulation to treat vestibulodynia: a randomized controlled trial. BJOG. 2008; 115:1165-70
  268. De Andres J, Sanches-Lopez N, Ascensio-Samper J, et al. Peripheral subcutaneous vulvar stimulation in the management of severe and refractory vulvodynia. Obstet Gynecol 2013; 121(Pt 2, Suppl 1):495-98
  269. De Andres J, Sanches-Lopez N, Ascensio-Samper J, et al. Peripheral subcutaneous vulvar stimulation in the management of severe and refractory vulvodynia. Obstet Gynecol 2013; 121(Pt 2, Suppl 1):495-98
  270. Erdine S, Bilir A, Cosman E, et al. Ultrastructural changes in axons following exposure to pulsed radiofrequency fields. Pain Pract. 2009; 9:407-17
  271. Rigaud J, Delavierre D, Sibert L, Labat J. sympathetic nerve block in the management of chronic pelvic and perineal pain. Prog Urol. 2010; 20:1124-31.
  272. Whitmore K, Payne C, Diokno A, Lubkan J. Sacral neuromodulation in patients with interstitial cystitis: a multi center clinical trial. Int Urogynecol J Pelvic Floor Dysfunct. 2003; 14:305-8
  273. Alo K, Yland M, Redko V, et al. Lumbar and sacral nerve root stimulation (NRS) in the treatment of chronic pain: a novel anatomic approach and neuro stimulation technique. Neuromodulation 1999; 2:23-31.
  274. Ramsay L, Wright J, Fischer J. Sacral neuromodulation the treatment of vulvar vestibulitis syndrome. Obstet Gynecol 2009; 114:487-89
  275. Whiteside J, Walters M, Mikhail N. spinal cord stimulation for intractable vulvar pain- a case report. J Reprod Med. 2003; 48:821-23
  276. Hofmann SG, Sawyer AT, Fang A. The empirical status of the “New Wave” of cognitive behavioral therapy. Psych Clin of North America, 2010; 33(3):701-10
  277. Basson R. The recurrent pain and sexual sequelae of provoked vestibulodynia: a perpetuating cycle. J Sex Med 2012;9:2077-92.
  278. Lazar SW, Kerr CE, Wassermann RH, et al. Meditation experience is associated with increased cortical thickness. Neuroreport 2005; 16(17):1893-7
  279. Hassett AL, Gevirtz RN. Nonpharmacologic treatment for fibromyalgia: patient education, cognitive behavioral therapy, relaxation techniques, and complementary and alternative medicine. Rheum Dis Clin North Am. 2009; 35 (2): 393–407.
  280. Landry T, Bergeron S, Dupuis MJ, Desrochers G. The treatment of provoked vestibulodynia: a critical review. Clin J Pain. 2008;24(2):155-171
  281. Bergeron S, Binik YM, Khalife S, et al. A randomized comparison of group cognitive-behavioral therapy, surface electromyographic biofeedback, and vestibulectomy in the treatment of dyspareunia resulting from vulvar vestibulitis. Pain. 2001; 91:297-306
  282. ter Kuile MM, Weijenborg PT. A cognitive-behavioral group program for women with vulvar vestibulitis syndrome (VVA): factors associated with treatment success. J Sex Marital Ther. 2006; 32:199-213
  283. Eccleston C, Williams A, Morley S. Psychological therapies for the management of chronic pain (including headaches) in adults. Cochrane Database Sys Rev 2009; (15):CD007407
  284. Koyama T, McHaffie JG, Laurienti PJ, Coghill RC. The subjective experience of pain: Where expectations become reality. Proc Natl Acad Sci U S A 2005; 102:12950-5
  285. Lindstrom S, Kvist LJ. Treatment of provoked vulvodynia in a Swedish cohort using desensitization exercises and cognitive behavioral therapy. BMC Womens Health. 2015 Nov 25; 15(1):108
  286. Guillet AD, Ciriono NH, Hart KD, Leclair CM. Mindfulness-based group cognitive behavior therapy for provoked localized vulvodynia: a randomized controlled trial. J Low Genit Tract Dis 2019;23:170-175
  287. Kandyba K, Binik YM. Hypnotherapy as a treatment for vulvar vestibulitis syndrome: a case report. J Sex Marital Ther. 2003; 29:237-242
  288. Pukall CF, Kandyba K, Amsel R, et al. Efficacy of hypnosis for the treatment of vulvar vestibulitis syndrome: a preliminary investigation. J Sex Med. 2007; 4:417-425
  289. Fowler RS. Vulvar vestibulitis: response to hypocontactant vulvar therapy. J Low Genit Tract Dis. 2000;4:200-203.
  290. Danielsson I, Sjoberg I, Ostman C. Acupuncture for the treatment of vulvar vestibulitis: a pilot study. Acta Obstet Gynecol Scand. 2001; 80:437-444.
  291. Woodruff JD, Parmley TH. Infection of the minor vestibular gland. Obstet Gynecol. 1983; 62:609-612.
  292. Goetsch MF. Simplified surgical revision of the vulvar vestibule for vulvar vestibulitis. Am J Obstet Gynecol. 1996; 174:1701-1705
  293. De Andres J, Sanches-Lopez N, Asensio-Samper J, et al. Vulvodynia–an evidence based literature review and proposed treatment algorithm. Pain Practice 2015 Jan 12. doi: 10. 1111/papr.12274. {Epub ahead of print]
  294. De Andres J, Sanches-Lopez N, Asensio-Samper J, et al. Vulvodynia–an evidence based literature review and proposed treatment algorithm. Pain Practice 2015 Jan 12. doi: 10. 1111/papr.12274. {Epub ahead of print]
  295. Eanes A, Bair E, Martin C, Iyer P, Zalnoun D. Psychosexual correlates of persistent postsurgical pain in patients with vulvodynia. Int J Gynaecol Obstet; 2011; 113:225-28.
  296. Traas M, Beakers R, Dony J, et al. Surgical treatment for the vulvar vestibulitis syndrome. Obstet Gynecol. 2006; 107:256-62.
  297. Goldstein A, Klingman D, Johnson C, Marinoff S. Surgical treatment of vulvar vestibulitis syndrome: outcome assessment derived from a postoperative questionnaire. J Sex Med. 2006; 3:923-31.
  298. Goetsch M. Patients’ assessments of a superficial modified vestibulectomy for vestibulodynia. J Reprod Med 2008; 53:407-12.
  299. Tommola P, Unkila-Kallio L, Paavonen J. Long-term well-being after surgical or conservative treatment of severe vulvar vestibulitis. Acta Obstet Gynecol Scand. 2012; 91:1086-93
  300. Bergerson S, Binik Y, Khalife S, et al. A randomized comparison of group cognitive-behavioral therapy, surface electromyographic biofeedback, and vestibulectomy in the treatment of dyspareunia resulting from vulvar vestibulitis. Pain. 2001; 91:297-306.
  301. Bohm-Starke N, Rylander E. Surgery for localized, provoked vestibulodynia–A long-term follow-up study. J Reprod Med. 2008; 5:83-9.
  302. Granot M, Zimmer E, et al. Association between quantitative sensory testing, treatment choice, and subsequent pain reduction in vulvar vestibulitis syndrome. J Pain. 2004; 5:226-32.
  303. Schneider D, Yaron M, Butkovsky I et al. Outcome of surgical treatment for superficial dyspareunia from vulvar vestibulitis. J Reprod Med. 2001; 46:227-31.
  304. Tommala P. Unkila-Kallio L, Paavonen J. Long-term follow up of posterior vestibulectomy for treating vulvar vestibulitis. Acta Obstet Gynecol Scand. 2011; 90:1225-31.
  305. Andrews JC. Vulvodynia interventions- systematic review and evidence grading. Obstet Gynecol Survey. 2011:66(5):299-315.
  306. Daniels J, Gray R, Hills RK, et al on behalf of the LUNA Trial Collaboration. Laparoscoic uterosacral nerve ablation for alleviating chronic pelvic pain- a randomized controlled trial. JAMA. 2009; 302:955-61.
  307. Foster DC, Kotok MB, Huang LS, Watts A, Oakes D, et al. Oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trial. Obstet Gynecol. 2010; 116(3):583-93.
  308. Nyirjesy, P, Lev-Sagie A, Mathew L, Culhane JF. Topical amitriptyline-baclofen cream for the treatment of provoked vestibulodynia. J Low Gen Tract Dis. 2009; 13(4):230-236.
  309. Petersen CD, Giraldi A, Lundvall L, et al. botulinum toxin type A- a novel treatment for provoked vestibulodynia? Results from a randomized, placebo controlled, double blinded study. J Sex Med. 2009;6:2523-2537.
  310. Landry T, Bergeron S, Dupuis MJ, Desrochers G. The treatment of provoked vestibulodynia: a critical review. Clin J Pain. 2008;24(2):155-171.
  311. De Andres J, Sanches-Lopez N, Asensio-Samper J, et al. Vulvodynia-an evidence based literature review and proposed treatment algorithm.Pain Practice 2015 Jan 12. doi: 10. 1111/papr.12274. {Epub ahead of print]
  312. Tommola P, Unkila-Kallio L. Paavonen J. Long-term well-being after surgical or conservative treatment of severe vulvar vestibulitis. Acta Obstet Gynecol Scand 2012 Sep;91(9):1086-93.
  313. Aalto A, Huhtala H, Maenpaa J, Staff S. Combination of treatments with or without surgery in localized provoked  vestibulodynia after three years of follow -up. Biorese Open Access 2019 Mar 8;8(1):25-31.